

GB 99/4232

PA 192269

REC'D 11 FEB 2000

WIPO

PCT

EJU



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

09/868131

United States Patent and Trademark Office

January 05, 2000

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM
THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK
OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT
APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A
FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/112,217

FILING DATE: December 14, 1998

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)



By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS

T. LAWRENCE

Certifying Officer

Please type a plus sign (+) in box



Sheet Number:

002.00070

PROVISIONAL APPLICATION FOR PATENT COVER SHEET (Small Entity)

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

INVENTOR(S)/APPLICANT(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
Philip		Cohen		Dundee, United Kingdom	
<input type="checkbox"/> Additional inventors are being named on page 2 attached hereto					
TITLE OF THE INVENTION (280 characters max)					
METHODS					
CORRESPONDENCE ADDRESS					
Direct all correspondence to:					
<input type="checkbox"/> Customer Number				Place Customer Number Bar Code Label here	
OR					
<input checked="" type="checkbox"/> Firm or Individual Name		Susan J. Braman, Esq.			
Address		Braman & Rogalskyj, LLP			
Address		P.O. Box 352			
City		Canandaigua	State	New York	ZIP 14424
Country		United States	Telephone	(716) 393-3002	Fax (716) 393-3001
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/>	Specification	Number of Pages	76	<input type="checkbox"/>	Small Entity Statement
<input checked="" type="checkbox"/>	Drawing(s)	Number of Sheets	10	<input checked="" type="checkbox"/>	Other (specify) Express Mail Cert EE459571777US
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)					
<input checked="" type="checkbox"/>	A check or money order is enclosed to cover the filing fees				FILING FEE AMOUNT
<input type="checkbox"/>	The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:				\$75.00
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/>	No.				
<input type="checkbox"/>	Yes, the name of the U.S. Government agency and the Government contract number are				

Respectfully submitted,

SIGNATURE

Peter Rogalskyj

Date

12/14/1998

TYPED or PRINTED NAME

Peter Rogalskyj

REGISTRATION NO.
(if appropriate)

38,601

TELEPHONE

(716) 393-3004

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, DC 20231

TITLE:

METHODS

INVENTOR:

Philip Cohen

DOCKET NO:

002.00070

0044227-134498

1
METHODS

The present invention relates to screening methods for new drugs or lead compounds.

- 5 Protein kinase B (PKB) (also called c-Akt or RAC kinase) is believed to play a key role in mediating many of the metabolic actions of insulin, as well as the anti-apoptotic effects of survival factors such as insulin-like growth factor-1 (IGF-1) (reviewed in [1,2]). PKB is activated within a few minutes in response to insulin or survival factors *via* a
10 phosphatidylinositol (PtdIns) 3-kinase dependent mechanism [3-5]. Activation results from the phosphorylation of Thr308 and Ser473, and the phosphorylation of both residues is prevented by inhibitors of PtdIns 3-kinase [6]. Thr308, which is located in the "activation loop" between subdomains VII and VIII of the catalytic domain, is phosphorylated by 3-
15 phosphoinositide-dependent protein kinase-1 (PDK1) [7-9], while Ser473 lies close to the C-terminus and is phosphorylated by a distinct enzyme termed PDK2 that has yet to be characterised.

The activation of PKB by PDK1 *in vitro* only takes place in the presence
20 of lipid vesicles containing PtdIns(3,4,5)P₃, the product of the PtdIns 3-kinase reaction, and results from the interaction of this "second messenger" with the pleckstrin homology (PH) domains of both PKB and PDK1 [9, 10].

- 25 PtdIns(3,4,5)P₃ is associated with the inner leaflet of the plasma membrane. The insulin or IGF-1 induced increase in PtdIns(3,4,5)P₃ is therefore accompanied by the recruitment of PKB from the cytosol to the plasma membrane where it becomes activated [12, 13]. Membrane recruitment appears to facilitate activation by PDK1 and PDK2 [12].

PDK1 binds to PtdIns(3,4,5)P₃ much more avidly than does PKB [10], and an interaction of PDK1 with the low levels of PtdIns(3,4,5)P₃ present under basal conditions may explain, at least in part, its constitutive association with the plasma membrane. Translocation of PDK1 from the cytosol to the plasma membrane in response to IGF-1 or PDGF may occur [14].

The amino acid sequence immediately C-terminal to Thr308 of PKB is similar to that found in other protein kinases that play important roles in signal transduction, such as p70 S6 kinase and protein kinase C (Fig 1). PDK1 activates p70 S6 kinase [15, 16], PKC δ and PKC ζ [17, Chou *et al* (1998) *Curr Biol* 8, 1069-1077] *in vitro*, and in cotransfection experiments, by phosphorylating the residue equivalent to Thr308 of PKB. The activation of p70 S6 kinase by PDK1 *in vitro* is not affected by PtdIns(3,4,5)P₃.

Like PKB, p70 S6 kinase and PKC contain the proposed consensus sequence for phosphorylation by PDK2 (Phe-Xaa-Xaa-(Phe/Tyr)-(Ser/Thr)-(Phe/Tyr)), which is always located 160-165 residues C-terminal to the PDK1 phosphorylation site (Fig 1). These observations suggest that PDK1 and PDK2 may participate together in the activation of a number of protein kinases. PDK2 has not been characterised.

Serum and glucocorticoid-induced protein kinase (SGK) was originally identified in a differential screen aimed at finding glucocorticoid-inducible transcripts [18]. The levels of SGK mRNA and protein are both elevated 5-10 fold, with a half time of 30 min in Rat2 fibroblasts, following cell stimulation with serum or glucocorticoids [19]. SGK is also induced in response to other stimuli, such as follicle-stimulating hormone [20],

increased extracellular osmolarity [21], injury of the brain [22, 23] and by transfection of mammary epithelial cells with p53 [24]. However, the glucocorticoid-stimulated induction of SGK is suppressed by wild type p53 in Rat2 fibroblasts, but not by mutant p53 [25].

5

The structure of SGK is similar to PKB, but it lacks a PH domain. The catalytic domain of SGK is 54% identical to PKB, 50% identical to p70 S6 kinase and 48% identical to PKC.

- 10 We demonstrate here that SGK is activated by IGF-1 or an oxidative stress in 293 cells via a PtdIns 3-kinase-dependent pathway. Activation appears to result from phosphorylation. Further, SGK possesses a threonine residue at the position equivalent to Thr308 of PKB and a serine residue equivalent to Ser473, and the sequences surrounding these residues are
- 15 consistent with an ability to be phosphorylated by PDK1 and PDK2 (Fig 1). Activation appears to result from phosphorylation of the residues equivalent to Thr308 and Ser473, and the residue equivalent to Thr308 is phosphorylated and SGK activated by PDK1 *in vitro*. SGK preferentially phosphorylates serine and threonine residues that lie in an Arg-Xaa-Arg-
- 20 Xaa-Xaa-(Ser/Thr)- motif, and inactivates glycogen synthase kinase-3 (GSK3) at similar rates to PKB *in vitro*.

- A first aspect of the invention is a method of activating serum and glucocorticoid-induced protein kinase (SGK) wherein the SGK is
- 25 phosphorylated. The SGK that is activated by the method may be partially or fully deactivated/dephosphorylated SGK.

A further aspect of the invention is a method of reducing the activity of SGK wherein the SGK is dephosphorylated. The SGK the activity of which is reduced may be partially or fully activated/phosphorylated SGK.

- 5 By "activating" is meant that the enzymatic activity of SGK is increased. By "reducing the activity" is meant that the enzymatic activity of SGK is reduced. The enzymatic activity that may be increased or reduced is protein kinase activity, preferably Serine/Threonine protein kinase activity ie the phosphorylation of a protein/polypeptide on one or more serine or
- 10 threonine residues. The enzymatic activity may be increased or reduced by an alteration in the V_{max} or the K_m (or both) of the SGK for a particular substrate. For example, activity may be increased by an increased V_{max} or decreased K_m . It will be appreciated that it may not be necessary to determine the value of either V_{max} or K_m in order to determine whether the
- 15 SGK has been activated or deactivated. It will be appreciated that dephosphorylated (deactivated) SGK may retain some enzymatic activity.

- Activity may be measured as the amount of a substrate phosphorylated in a given time; a change of activity may therefore be detected as a change in
- 20 the amount of substrate (for example, at a single concentration) that is phosphorylated in a given time, as described in Example 1. The substrate may be a polypeptide comprising the consensus sequence Arg-X(X/Arg)-X-X-(Ser/Thr)-Z where X indicates any amino acid, X/Arg indicates any amino acid, with a preference for arginine, and Z indicates that the amino
- 25 acid residue is preferably a hydrophobic residue. An example of such a polypeptide is the peptide Crosstide (GRPRTSSFAEG). The underlined residue may be phosphorylated by the said protein kinase. Other examples of polypeptides that may be substrates of SGK are shown in

Table 1. Glycogen synthase kinase-3 (GSK3) may be a substrate of SGK, as discussed in Example 1.

5 It will be appreciated that if the SGK is already phosphorylated, further phosphorylation may not be possible and/or may not lead to further activation. Further, if the SGK is already partially dephosphorylated, then further dephosphorylation may not be possible and/or may not lead to further deactivation.

10 It will further be appreciated that SGK isolated from cells (either as an endogenous or recombinant polypeptide) may be heterogeneous with regard to its phosphorylation/activation state. For example, fully activated/phosphorylated, fully deactivated/dephosphorylated and/or partially activated/phosphorylated molecules of SGK may be present in a
15 single cell or group/culture of cells.

It is preferred that the activity is increased or decreased, as appropriate, by at least 2, preferably 5, 10, 15, 20, 25, 30 or 50-fold.

20 By serum and glucocorticoid-induced protein kinase (SGK) is included a polypeptide, preferably a protein kinase, encoded by I.M.A.G.E Consortium clone ID 42669 (which comprises a full-length cDNA from a human infant brain library identified as encoding human serum and glucocorticoid-induced protein kinase). The term serum and
25 glucocorticoid-induced protein kinase is well known to those skilled in the art (see, for example, references 18 to 25). The amino acid sequence of human serum and glucocorticoid-induced protein kinase may have the Genbank accession reference Y10032. The amino acid sequence of rat serum and glucocorticoid-induced protein kinase may have the Genbank

accession reference L01624. Nematode (*Caenorhabditis elegans*) serum and glucocorticoid-induced protein kinase may be encoded by a portion of the 26 kb fragment from chromosome 3 genomic DNA with the accession number 281140.

5

SGK, for example the activated or deactivated SGK obtained or obtainable by the above methods of the invention, may be useful, for example in screening methods, such as those set out below. Thus, it will be appreciated that the term SGK as used herein includes a polypeptide comprising the amino acid sequence of the polypeptide, preferably a protein kinase, encoded by I.M.A.G.E Consortium clone ID 42669 or a variant, fragment, fusion or derivative thereof, or a fusion of a said variant or fragment or derivative, wherein the said polypeptide is a protein kinase. It is preferred that the said polypeptide is a protein kinase that is capable of phosphorylating a polypeptide comprising the consensus Arg-X-(X/Arg)-X-X-(Ser/Thr)-Z where X indicates any amino acid, X/Arg indicates any amino acid, with a preference for arginine, and Z indicates that the amino acid residue is preferably a hydrophobic residue. An example of such a polypeptide is Crosstide (GRPRTSSFAEG). The underlined residue may be phosphorylated by the said protein kinase. Other examples of polypeptides that may be phosphorylated by the said protein kinase are shown in Table 1 and may include GSK3, as discussed in Example 1. It will be appreciated that the said protein kinase is not PKB (for example, PKB α), p70 S6 kinase, protein kinase C (for example, PKC δ or PKC ζ), MAPKAP kinase-1(Leighton *et al* (1995) *FEBS Lett* 375, 289-293) or MSK1 or MSK2 (see, for example, UK patent applications 9817303.2, filed 10 August 1998 and 9813467.9, filed 24 June 1998).

It will be appreciated that a said polypeptide may be useful, for example in some of the screening assays as set out below, even if it does not possess protein kinase activity as defined above. It will further be appreciated that the phosphorylation of such a polypeptide may be detected by means
 5 described herein other than by detecting a change in enzymatic, in particular protein kinase, activity of the polypeptide.

It is preferred that the SGK comprises an amino acid sequence corresponding to the consensus sequence B-T-F-C-G-T-(P/I)-(D/E)-Y-
 10 (L/I/M)-A-P-E, where B is a basic residue, the consensus sequence for phosphorylation of a polypeptide by PDK1, and/or the consensus sequence Phe-Xaa-Xaa-(Phe/Tyr)-(Ser/Thr)-(Phe/Tyr), the consensus sequence proposed for phosphorylation of a polypeptide by PDK2. Preferably both consensus sequences are present. Alternatively, the Ser/Thr in either
 15 consensus sequence may be replaced by an aspartate or glutamate (ie acidic) residue; it is preferred that only one such consensus sequence in a polypeptide is replaced in this way. It is preferred that the Ser/Thr in the consensus sequence for phosphorylation by PDK1 is not replaced in this way; as described in Example 1, replacement of Thr256 to Asp in human
 20 SGK may abolish activation of SGK.

By "variants" of the polypeptide we include insertions, deletions and substitutions, either conservative or non-conservative. In particular we include variants of the polypeptide where such changes do not
 25 substantially alter the activity of the said protein kinase.

By "conservative substitutions" is intended combinations such as Gly, Ala; Val, Ile, Leu; Asp, Glu; Asn, Gln; Ser, Thr; Lys, Arg; and Phe, Tyr.

It is particularly preferred if the SGK variant has an amino acid sequence which has at least 65% identity with the amino acid sequence of the polypeptide, preferably a protein kinase, encoded by I.M.A.G.E Consortium clone ID 42669, more preferably at least 70%, 71%, 72%, 73% or 74%, still more preferably at least 75%, yet still more preferably at least 80%, in further preference at least 85%, in still further preference at least 90% and most preferably at least 95% or 97% identity with the amino acid sequence defined above.

10

It is still further preferred if the SGK variant has an amino acid sequence which has at least 65% identity with the amino acid sequence of the catalytic domain of the polypeptide, preferably a protein kinase, encoded by I.M.A.G.E Consortium clone ID 42669, more preferably at least 70%, 71%, 72%, 73% or 74%, still more preferably at least 75%, yet still more preferably at least 80%, in further preference at least 83 or 85%, in still further preference at least 90% and most preferably at least 95% or 97% identity with the amino acid sequence defined above. It will be appreciated that the catalytic domain of a protein kinase-related polypeptide may be readily identified by a person skilled in the art, for example using sequence comparisons as described below, and as described in relation to SGK in, for example, Webster *et al* (1993) *Mol Cell Biol* 13(4), 2031-2040.

25 The percent sequence identity between two polypeptides may be determined using suitable computer programs, for example the GAP program of the University of Wisconsin Genetic Computing Group and it will be appreciated that percent identity is calculated in relation to polypeptides whose sequence has been aligned optimally.

The alignment may alternatively be carried out using the Clustal W program (Thompson *et al.*, 1994). The parameters used may be as follows:

- 5 Fast pairwise alignment parameters: K-tuple(word) size; 1, window size; 5, gap penalty; 3, number of top diagonals; 5. Scoring method: x percent. Multiple alignment parameters: gap open penalty; 10, gap extension penalty; 0.05.

Scoring matrix: BLOSUM.

10

It is preferred that the SGK is a polypeptide which consists of the amino acid sequence of the protein kinase encoded by I.M.A.G.E Consortium clone ID 42669 or naturally occurring allelic variants thereof.

- 15 It is also preferred that the SGK is one of the following:

(1) a polypeptide encoded by I.M.A.G.E Consortium clone ID 42669 lacking the N-terminal 60 amino acids of full-length human SGK (for example Δ N-SKG(61-431) as described in Example 1)

- (2) full-length SGK or SGK lacking the N-terminal 60 amino acids, as described above, in which serine 422 (numbering of full-length SGK) is replaced by aspartate or glutamate (preferably aspartate) and/or threonine 256 is replaced by aspartate or glutamate or alanine

- (3) a fusion polypeptide of glutathione-S-transferase (GST) and any of the variants of SGK described above, for example a fusion protein comprising the GST encoded by the GST sequence of the plasmid pEBG2T, as known to those skilled in the art. Examples include GST- Δ N-SKG[S422D], as described in Example 1.

It will be appreciated that SGK in which threonine 256 (numbering of full-length SGK) is replaced, for example by an alanine, glutamate or aspartate residue, may not be capable of being significantly activated by phosphorylation and may therefore be less preferred than some other
5 SGKs for use in the screening methods of the invention. Thus, GST-SGK[T256D], GST-SGK[T256E], GST-SGK[T256A], as described in Example 1, may not be capable of being significantly activated by phosphorylation and may therefore be less preferred than some other SGKs for use in the screening methods of the invention.

10

It will further be appreciated that SGK in which serine 422 (numbering of full-length SGK) is replaced by an amino acid residue other than glutamate or aspartate (ie an acidic residue) or a residue that may be phosphorylated, for example by an alanine residue, may not be capable of being activated
15 by phosphorylation or may be less capable of being activated by phosphorylation than SGK in which serine 422 is not so replaced.

It will be appreciated that a mutated SGK which does not have any protein kinase activity ("kinase dead" mutant) may be phosphorylated in a similar
20 manner to SGK that does have protein kinase activity, but that no change in protein kinase activity may be discernible. Such a mutated SGK may be SGK in which lysine 127 (which may lie in the ATP binding site) is replaced by alanine, as described in Example 1..

25 SGK (as defined above) may be phosphorylated by phosphatidylinositol dependent kinase 1 (PDK1), or a variant, fragment, fusion or derivative thereof, or a fusion of a said variant, fragment or derivative. The term PDK1 is well known to those skilled in the art (see, for example, references 7 to 9) and includes, in particular, PDK1 as described and

expressed in reference 9 and in co-pending application PCT/GB98/00777. It is preferred that the said variant, fragment, fusion or derivative of PDK1, or a fusion of a said variant, fragment or derivative is a protein kinase, preferably a protein kinase capable of phosphorylating a polypeptide comprising an amino acid sequence corresponding to the consensus sequence B-T-F-C-G-T-(P/I)-(D/E)-Y-(L/I/M)-A-P-E. Such variants of PDK1 may be functional equivalents of PDK1 and include Pkh1 and Pkh2 from *Saccharomyces cerevisiae* as described in the UK or US patent application entitled "Screening Methods" filed on the same day as this application.

SGK may be dephosphorylated by a serine/threonine protein phosphatase, for example PP1 (Berndt *et al* (1987) *FEBS Lett* 223, 340-346), PP2C (Mann *et al* (1992) *Biochem et Biophys Acta* 1130, 100-104 or protein phosphorylase 2A (PP2A; da Cruz E Silva (1987) *FEBS Lett* 221, 415-422) or a variant, fragment, fusion or derivative any thereof, or a fusion of a said variant, fragment or derivative. PP1, PP2C or PP2A or a variant, fragment, fusion or derivative any thereof, or a fusion of a said variant, fragment or derivative is capable of dephosphorylating phosphorylase *a*. The terms PP1, PP2C, PP2A and phosphorylase *a* are well known to those skilled in the art. PP2A may be inactivated by microcystin-LR at 1 μ M.

A further aspect of the invention is the use of a serine/threonine protein phosphatase, for example PP1, PP2C, PP2A or a variant, fragment, fusion or derivative any thereof, or a fusion of a said variant, fragment or derivative (as defined above) in a method of deactivating and/or dephosphorylating SGK. The SGK may be phosphorylated SGK, as discussed above.

A still further aspect of the invention is the use of a protein kinase, preferably PDK1 or a variant, fragment, fusion or derivative thereof, or a fusion of a said variant, fragment or derivative (as defined above) in a method of activating and/or phosphorylating SGK. The SGK may be dephosphorylated SGK, as discussed above.

A further aspect of the invention is a method of activating SGK (as defined above) wherein SGK is phosphorylated on the residue equivalent to Thr256 of full-length human SGK. SGK (for example full-length human SGK and Δ N-SGK(61-431), may be phosphorylated on the residue equivalent to Thr 256 of full-length human SGK by PDK1. SGK may be activated by phosphorylation on this residue, as described in Example 1.

It will be appreciated that a protein kinase capable of phosphorylating SGK on the residue equivalent to Thr256 of full-length human SGK may be identified by determining whether any particular protein kinase is capable of activating SGK and/or determining what, if any residue of SGK may be phosphorylated by the said particular protein kinase, for example as described in Example 1.

By "residue equivalent to Thr256 of full-length human SGK" is included the meaning that the amino acid residue that occupies a position in the native three dimensional structure of a protein kinase corresponding to the position occupied by Thr 256 in the native three dimensional structure of human full-length SGK. It will be appreciated that Thr256 of human full-length SGK is located in the "activation loop" between subdomains VII and VIII of the catalytic domain.

Protein kinases show a conserved catalytic core, as reviewed in Johnson *et al* (1996) *Cell*, 85, 149-158 and Taylor & Radzio-Andzelm (1994) *Structure* 2, 345-355. This core folds into a small N-terminal lobe largely comprising anti-parallel β -sheet, and a large C-terminal lobe which is
5 mostly α -helical.

The residue equivalent to Thr 256 of full-length human SGK may be identified by alignment of the sequence of the polypeptide with that of full-length human SGK in such a way as to maximise the match between the
10 sequences. The alignment may be carried out by visual inspection and/or by the use of suitable computer programs, for example the GAP program of the University of Wisconsin Genetic Computing Group, which will also allow the percent identity of the polypeptides to be calculated. The Align program (Pearson (1994) in: *Methods in Molecular Biology, Computer*
15 *Analysis of Sequence Data, Part II* (Griffin, AM and Griffin, HG eds) pp 365-389, Humana Press, Clifton). Thus, residues identified in this manner are also "equivalent residues".

It will be appreciated that in the case of truncated forms of SGK or in
20 forms where simple replacements of amino acids have occurred it is facile to identify the "equivalent residue".

The sequence for human SGK is given, for example, in Webster *et al* (1993) *Mol cell Biol* 13(4), 2031-2040.

25

It will be appreciated that identification of the residue equivalent to Thr 256 may depend on the alignment of surrounding conserved residues.

- A further aspect of the invention is a method of activating SGK (as defined above) wherein SGK is phosphorylated on the residue equivalent to Ser422 of full-length human SGK. SGK (for example full-length human SGK and Δ N-SGK(61-431), may be phosphorylated on the residue equivalent to Ser
- 5 422 of full-length human SGK by a preparation containing PDK2 activity. SGK may be activated by phosphorylation on this residue, as described in Example 1. The method may be performed in a cell, for example a mammalian cell that is stimulated by, for example, IGF-1 and/or hydrogen peroxide. The method may comprise culturing a host cell comprising a
- 10 recombinant polynucleotide or a replicable vector which encodes SGK, stimulating the cell, for example with IGF-1 and/or hydrogen peroxide and isolating said polypeptide from said host cell. Methods of cultivating host cells and isolating recombinant proteins are well known in the art.
- 15 The residue equivalent to Ser422 of full-length human SGK may be identified by methods analagous to those described above for the residue equivalent to Thr256 of full-length human SGK. Ser422 of human full-length SGK lies towards the C-terminus of the polypeptide.
- 20 A preparation containing PDK2 activity may phosphorylate polypeptides comprising an amino acid sequence corresponding to the consensus sequence Phe-Xaa-Xaa-Phe/Tyr-Ser/Thr-Phe/Tyr.

- SGK may be phosphorylated on the residue equivalent to Ser422 of full-
- 25 length human SGK, for example *in vitro*, by a protein kinase that may not have the physiological characteristics of PDK2 or may not require the consensus sequence thought to be required by PDK2. Thus, *in vitro*, SGK may be phosphorylated by a protein kinase that may not phosphorylate SGK in a physiologically relevant manner *in vivo* and may not correspond

to an activity identified as PDK2. This may be analagous to the phosphorylation *in vitro* of PKB α on the site equivalent to Ser422 of SGK (Ser473) by MAPKAP Kinase-2 (Alessi *et al* (1996) *EMBO J* 15, 6541-6551). MAPKAP Kinase-2 does not require the consensus sequence
 5 identified as required by PDK2.

It will be appreciated that a protein kinase that is capable of phosphorylating the residue equivalent to Ser422 of full-length human SGK may be identified by methods similar to those described above and in
 10 Example 1 for identifying a protein kinase that may phosphorylate the residue equivalent to Thr256 of full-length human SGK.

The phosphorylation of SGK may be PtdIns(3,4,5)P₃ dependent. In particular, the phosphorylation of the residue equivalent to Ser422, for
 15 example by a preparation containing PDK2 activity, may be PtdIns(3,4,5)P₃ dependent. Thus, *in vivo*, the phosphorylation of the residue equivalent to Ser422 may be dependent upon the activity of PtdIns 3-kinase.

20 The phosphorylation of SGK on the residue equivalent to Thr256 may be dependent upon the phosphorylation of the residue equivalent to Ser 422. Alternatively, if serine 422 is replaced by an aspartate residue, as described in Example 1, then the phosphorylation of the residue equivalent to Thr256, for example by PDK1, may be potentiated. Thus, the
 25 phosphorylation of Thr256 may require that (or be enhanced if) the residue equivalent to Ser422 is phosphorylated or is replaced by an aspartate residue.

A further aspect of the invention is a fusion polypeptide of SGK or a variant, fragment or derivative thereof. The fusion polypeptide may comprise, for example, a fragment of SGK or variant or derivative thereof wherein the N-terminal about 20, 30, 40, 50 or 60 amino acids of human
5 full-length SGK are deleted. The fusion polypeptide may further comprise glutathione-S-transferase. The glutathione-S-transferase may be fused to the N-terminus or C-terminus of SGK or the said fragment variant or derivative thereof; preferably it is fused to the N-terminus, for example as shown in Example 1.

10

It is particularly preferred that the fusion polypeptide has at least 5%, 10%, 15%, 20%, 25% or 30% of the enzyme activity of SGK with respect to the phosphorylation of Crosstide (GRPRTSSFAEG; see Example 1). It is more preferred if the fusion polypeptide has at least
15 50%, preferably at least 70% and more preferably at least 90% of the enzyme activity of SGK with respect to the phosphorylation of Crosstide. It is preferred that the fusion polypeptide comprises the residue equivalent to Thr256 and/or the residue equivalent to Ser 422 of full-length human SGK. It will be appreciated that a fusion polypeptide with low enzymic
20 activity may be useful in applications including high throughput screening, for example if it expressed in high amounts or may be easily purified or stored. However, it will be appreciated that fusion polypeptides which are devoid of enzymatic activity may nevertheless also be useful, for example by interacting with another polypeptide, or as antigens in raising
25 antibodies, or the phosphorylation of such variants or fusions or derivatives or fragments may be measured. It will be appreciated that fusions of PKB α , PKC δ , PKC ξ , p70 S6 kinase, MSK1 and MSK2 are not polypeptides of the invention, unless they include all or part of SGK.

A further aspect of the invention is a polypeptide comprising the amino acid sequence of human SGK or a fragment, variant, derivative or fusion thereof wherein the residue equivalent to serine 422 of full-length human SGK is replaced (for example by an aspartate, glutamate or alanine residue) and/or the residue equivalent to threonine 256 of full-length human SGK is replaced (for example by an alanine residue), and/or the residue equivalent to lysine 127 of full-length human SGK is replaced (for example by an alanine residue). The residue equivalent to lysine 127 of full-length human SGK may be identified in a manner analogous to that described above for the residue equivalent to serine 422, and may lie in the ATP binding site. The residue equivalent to serine 422 of full-length human SGK may be replaced by a residue that is capable of carrying a negative charge (for example an aspartate or glutamate residue), which may mimic the effect of phosphorylation of serine 422. Alternatively, the residue equivalent to serine 422 of full-length human SGK may be replaced by a residue, for example alanine, that cannot be phosphorylated and is not capable of carrying a negative charge, and preferably is of a similar bulk to serine or threonine. The residue equivalent to threonine 256 of full-length human SGK may similarly be replaced by a residue that is capable of carrying a negative charge (for example an aspartate or glutamate residue), or by a residue, for example alanine, that cannot be phosphorylated and is not capable of carrying a negative charge and preferably is of a similar bulk to serine or threonine. The residue equivalent to lysine 127 of full-length human SGK may be replaced by a residue that is not capable of carrying a positive charge, for example an alanine residue.

It is preferred that the residue equivalent to serine 422 of full-length human SGK is replaced by an aspartate residue and the residues equivalent

to threonine 256 and lysine 127 of the full-length human SGK are unmutated, ie are threonine and lysine respectively. It is further preferred that the N-terminal 20, 30, 40, 50 or 60 amino acids of full-length human SGK are deleted.

5

It will be appreciated that a polypeptide comprising the amino acid sequence of human SGK or a fragment, variant, derivative or fusion thereof wherein the residue equivalent to threonine 256 of full-length human SGK is replaced by an alanine residue, and/or the residue
10 equivalent to lysine 127 of full-length human SGK is replaced by an alanine residue may not be capable of being activated by phosphorylation and/or may be devoid of protein kinase activity, respectively, and therefore may not be useful in screening methods of the invention.

15 A further aspect of the invention is a polynucleotide encoding a polypeptide of the invention.

A still further aspect of the invention is a recombinant polynucleotide suitable for expressing a polypeptide of the invention. The polynucleotide
20 may be a vector suitable for replication and/or expression of the polypeptide in a mammalian/eukaryotic cell.

The polynucleotide or recombinant polynucleotide may be DNA or RNA, preferably DNA. The polynucleotide may or may not contain introns in
25 the coding sequence; preferably the polynucleotide is or comprises a cDNA.

Site-directed mutagenesis or other techniques can be employed to create single or multiple mutations, such as replacements, insertions, deletions,

5042347-124498

and transpositions, as described in Botstein and Shortle, "Strategies and Applications of *In Vitro* Mutagenesis," *Science*, 229: 193-210 (1985), which is incorporated herein by reference. Polymerase chain reaction based methods of site-directed mutagenesis may be used, as well known to those skilled in the art, for example as described in Example 1.

By "suitable for expressing" is mean that the polynucleotide is a polynucleotide that may be translated to form the polypeptide, for example RNA, or that the polynucleotide (which is preferably DNA) encoding the polypeptide of the invention is inserted into an expression vector, such as a plasmid, in proper orientation and correct reading frame for expression. The polynucleotide may be linked to the appropriate transcriptional and translational regulatory control nucleotide sequences recognised by any desired host; such controls may be incorporated in the expression vector.

Characteristics of vectors suitable for replication in mammalian/eukaryotic cells are well known to those skilled in the art, and examples are given below. It will be appreciated that a vector may be suitable for replication in both prokaryotic and eukaryotic cells.

A variety of methods have been developed to operably link polynucleotides, especially DNA, to vectors for example via complementary cohesive termini. Suitable methods are described in Sambrook *et al* (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

A desirable way to modify the DNA encoding a polypeptide of the invention is to use the polymerase chain reaction as disclosed by Saiki *et al* (1988) *Science* 239, 487-491. This method may be used for introducing

the DNA into a suitable vector, for example by engineering in suitable restriction sites, or it may be used to modify the DNA in other useful ways as is known in the art.

5 In this method the DNA to be enzymatically amplified is flanked by two specific primers which themselves become incorporated into the amplified DNA. The said specific primers may contain restriction endonuclease recognition sites which can be used for cloning into expression vectors using methods known in the art.

10

The DNA (or in the case of retroviral vectors, RNA) is then expressed in a suitable host to produce a polypeptide comprising the compound of the invention. Thus, the DNA encoding the polypeptide constituting the compound of the invention may be used in accordance with known techniques, appropriately modified in view of the teachings contained herein, to construct an expression vector, which is then used to transform an appropriate host cell for the expression and production of the polypeptide of the invention. Such techniques include those disclosed in US Patent Nos. 4,440,859 issued 3 April 1984 to Rutter *et al*, 4,530,901 issued 23 July 1985 to Weissman, 4,582,800 issued 15 April 1986 to Crawl, 4,677,063 issued 30 June 1987 to Mark *et al*, 4,678,751 issued 7 July 1987 to Goeddel, 4,704,362 issued 3 November 1987 to Itakura *et al*, 4,710,463 issued 1 December 1987 to Murray, 4,757,006 issued 12 July 1988 to Toole, Jr. *et al*, 4,766,075 issued 23 August 1988 to Goeddel *et al* and 4,810,648 issued 7 March 1989 to Stalker, all of which are incorporated herein by reference.

The DNA (or in the case of retroviral vectors, RNA) encoding the polypeptide constituting the compound of the invention may be joined to a

wide variety of other DNA sequences for introduction into an appropriate host. The companion DNA will depend upon the nature of the host, the manner of the introduction of the DNA into the host, and whether episomal maintenance or integration is desired.

5

Generally, the DNA is inserted into an expression vector, such as a plasmid, in proper orientation and correct reading frame for expression. If necessary, the DNA may be linked to the appropriate transcriptional and translational regulatory control nucleotide sequences recognised by the
10 desired host, although such controls are generally available in the expression vector. The vector is then introduced into the host through standard techniques. Generally, not all of the hosts will be transformed by the vector. Therefore, it will be necessary to select for transformed host cells. One selection technique involves incorporating into the expression
15 vector a DNA sequence, with any necessary control elements, that codes for a selectable trait in the transformed cell, such as antibiotic resistance. Alternatively, the gene for such selectable trait can be on another vector, which is used to co-transform the desired host cell.

20 Host cells that have been transformed by the recombinant DNA of the invention are then cultured for a sufficient time and under appropriate conditions known to those skilled in the art in view of the teachings disclosed herein to permit the expression of the polypeptide, which can then be recovered.

25

It will be appreciated that the host cell, for example a mammalian cell such as 293 cells as described in Example 1, may be stimulated, for example using IGF-1 or hydrogen peroxide, such that the SGK polypeptide may be phosphorylated and/or activated in the host cell. The

activated SGK polypeptide may then be recovered, if necessary in the presence of phosphatase inhibitors, for example microcystin, for example as described in Example 1. Recovery may entail purification on glutathione-Sepharose, as described in Example 1.

5

293 cells are human transformed primary embryonal kidney cells that may be obtained from the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Maryland 20852-1776; catalogue reference ATCC CRL 1573.

10

Many expression systems are known, including bacteria (for example *E. coli* and *Bacillus subtilis*), yeasts (for example *Saccharomyces cerevisiae*), filamentous fungi (for example *Aspergillus*), plant cells, animal cells and insect cells.

15

The vectors include a prokaryotic replicon, such as the ColE1 *ori*, for propagation in a prokaryote, even if the vector is to be used for expression in other, non-prokaryotic, cell types. The vectors can also include an appropriate promoter such as a prokaryotic promoter capable of directing the expression (transcription and translation) of the genes in a bacterial host cell, such as *E. coli*, transformed therewith.

20

A promoter is an expression control element formed by a DNA sequence that permits binding of RNA polymerase and transcription to occur.

25

Promoter sequences compatible with exemplary bacterial hosts are typically provided in plasmid vectors containing convenient restriction sites for insertion of a DNA segment of the present invention.

Typical prokaryotic vector plasmids are pUC18, pUC19, pBR322 and pBR329 available from Biorad Laboratories, (Richmond, CA, USA) and pTrc99A and pKK223-3 available from Pharmacia, Piscataway, NJ, USA.

- 5 A typical mammalian cell vector plasmid is pSVL available from Pharmacia, Piscataway, NJ, USA. This vector uses the SV40 late promoter to drive expression of cloned genes, the highest level of expression being found in T antigen-producing cells, such as COS-1 cells.
- 10 An example of an inducible mammalian expression vector is pMSG, also available from Pharmacia. This vector uses the glucocorticoid-inducible promoter of the mouse mammary tumour virus long terminal repeat to drive expression of the cloned gene.
- 15 Useful yeast plasmid vectors are pRS403-406 and pRS413-416 and are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Plasmids pRS403, pRS404, pRS405 and pRS406 are Yeast Integrating plasmids (YIPs) and incorporate the yeast selectable markers *HIS3*, *TRP1*, *LEU2* and *URA3*. Plasmids pRS413-416 are Yeast
- 20 Centromere plasmids (YCps).

- The present invention also relates to a host cell transformed with a polynucleotide vector construct of the present invention. The host cell can be either prokaryotic or eukaryotic. Bacterial cells are preferred
- 25 prokaryotic host cells and typically are a strain of *E. coli* such as, for example, the *E. coli* strains DH5 available from Bethesda Research Laboratories Inc., Bethesda, MD, USA, and RR1 available from the American Type Culture Collection (ATCC) of Rockville, MD, USA (No ATCC 31343). Preferred eukaryotic host cells include yeast, insect and

mammalian cells, preferably vertebrate cells such as those from a mouse, rat, monkey or human fibroblastic cell line. Yeast host cells include YPH499, YPH500 and YPH501 which are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Preferred mammalian host cells include human embryonic kidney 293 cells (see Example 1), Chinese hamster ovary (CHO) cells available from the ATCC as CCL61, NIH Swiss mouse embryo cells NIH/3T3 available from the ATCC as CRL 1658, and monkey kidney-derived COS-1 cells available from the ATCC as CRL 1650. Preferred insect cells are Sf9 cells which can be transfected with baculovirus expression vectors.

Transformation of appropriate cell hosts with a DNA construct of the present invention is accomplished by well known methods that typically depend on the type of vector used. With regard to transformation of prokaryotic host cells, see, for example, Cohen *et al* (1972) *Proc. Natl. Acad. Sci. USA* 69, 2110 and Sambrook *et al* (1989) *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. Transformation of yeast cells is described in Sherman *et al* (1986) *Methods In Yeast Genetics, A Laboratory Manual*, Cold Spring Harbor, NY. The method of Beggs (1978) *Nature* 275, 104-109 is also useful. With regard to vertebrate cells, reagents useful in transfecting such cells, for example calcium phosphate and DEAE-dextran or liposome formulations, are available from Stratagene Cloning Systems, or Life Technologies Inc., Gaithersburg, MD 20877, USA.

25

Electroporation is also useful for transforming and/or transfecting cells and is well known in the art for transforming yeast cell, bacterial cells, insect cells and vertebrate cells.

For example, many bacterial species may be transformed by the methods described in Luchansky *et al* (1988) *Mol. Microbiol.* **2**, 637-646 incorporated herein by reference. The greatest number of transformants is consistently recovered following electroporation of the DNA-cell mixture
 5 suspended in 2.5X PEB using 6250V per cm at 25:FD.

Methods for transformation of yeast by electroporation are disclosed in Becker & Guarente (1990) *Methods Enzymol.* **194**, 182.

10 Successfully transformed cells, ie cells that contain a DNA construct of the present invention, can be identified by well known techniques. For example, cells resulting from the introduction of an expression construct of the present invention can be grown to produce the polypeptide of the invention. Cells can be harvested and lysed and their DNA content
 15 examined for the presence of the DNA using a method such as that described by Southern (1975) *J. Mol. Biol.* **98**, 503 or Berent *et al* (1985) *Biotech.* **3**, 208. Alternatively, the presence of the protein in the supernatant can be detected using antibodies as described below.

20 In addition to directly assaying for the presence of recombinant DNA, successful transformation can be confirmed by well known immunological methods when the recombinant DNA is capable of directing the expression of the protein. For example, cells successfully transformed with an expression vector produce proteins displaying appropriate antigenicity.
 25 Samples of cells suspected of being transformed are harvested and assayed for the protein using suitable antibodies.

Thus, in addition to the transformed host cells themselves, the present invention also contemplates a culture of those cells, preferably a

monoclonal (clonally homogeneous) culture, or a culture derived from a monoclonal culture, in a nutrient medium.

5 A further aspect of the invention provides a method of making the polypeptide of the invention the method comprising culturing a host cell comprising a recombinant polynucleotide or a replicable vector which encodes said polypeptide, and isolating said polypeptide from said host cell. Methods of cultivating host cells and isolating recombinant proteins are well known in the art.

10

15 A still further aspect of the invention provides a method of making and activating the polypeptide of the invention the method comprising culturing a host cell, preferably a eukaryotic cell, comprising a recombinant polynucleotide or a replicable vector which encodes said polypeptide, stimulating the cell, for example with IGF-1 and/or hydrogen peroxide and isolating said polypeptide from said host cell. Methods of cultivating host cells and isolating recombinant proteins are well known in the art. The host cell may be a mammalian cell that is stimulated by, for example, IGF-1 and/or hydrogen peroxide, for example a 293 cell.

20

A further aspect of the invention is a polypeptide obtainable by the above methods of the invention.

25 A still further aspect of the invention is a method of identifying a compound that modulates the activity of SGK wherein activated SGK is used.

A further aspect of the invention is the use of activated SGK in a screening assay for a drug-like compound or lead compound for the development of

a drug-like compound. It will be appreciated that by a drug-like compound or lead compound for the development of a drug-like compound are included compounds that may be useful in medicine and compounds that may be useful in the development of a compound that may
 5 be useful in medicine. Examples of such screening assays may include the methods of the invention described below.

A further aspect of the invention is a method of identifying a compound that modulates the activity of SGK (as defined above), the method
 10 comprising contacting a compound with SGK and determining whether the activity of the said polypeptide is changed compared to the activity of the said SGK in the absence of said compound wherein the activity of SGK is measured by measuring the phosphorylation by SGK, in the presence of a suitable phosphate donor, of a polypeptide comprising an amino acid
 15 sequence corresponding to the consensus sequence (Arg/Lys; preferably Arg)-X-(X/Arg)-X-X-(Ser/Thr)-Z wherein X indicates ~~any amino acid~~, X/Arg indicates ~~any amino acid~~, with a preference for arginine, and Z indicates that ~~the amino acid residue is preferably a hydrophobic residue~~. The polypeptide ~~may be Crosstide or other suitable polypeptide described~~
 20 in Table 1 or preferably a physiological substrate of SGK, which may be GSK3.

It will be appreciated that in the methods of the invention wherein phosphorylation of a polypeptide may occur that the presence of a suitable
 25 phosphate donor may be required, as described for the above aspect of the invention. Suitable phosphate donors will be known to those skilled in the art and include ATP, for example as the magnesium salt (MgATP), as described in Example 1.

It is preferred for at least the above three aspects of the invention that the SGK is full-length human SGK or N-terminally truncated SGK (for example, 20, 30, 40, 50 or 60 amino acids of full-length human SGK may be deleted, such as in Δ N-SGK(61-431)) or a fusion (preferably a GST fusion) of full-length human SGK or N-terminally truncated SGK wherein the residue equivalent to serine 422 of full-length human SGK is replaced by an aspartate residue and the residues equivalent to threonine 256 and lysine 127 of the full-length human SGK are unmutated, ie remain as threonine and lysine respectively.

10

It is preferred that the SGK is activated by phosphorylation according to a method of the invention. It will be appreciated that if the SGK is an SGK in which the residue equivalent to serine 422 of full-length human SGK is replaced by an aspartate residue, for example the preferred SGK described above, that this residue will not be phosphorylated, but that the SGK may be activated by phosphorylation of the residue (preferably threonine) equivalent to threonine 256 of full-length human SGK.

It will be appreciated that the SGK may be phosphorylated and/or activated in a cell by stimulating the said cell with, for example, IGF-1 or hydrogen peroxide. The cell may be a eukaryotic, preferably mammalian, for example, 293 cell in which a recombinant SGK is expressed. The SGK may be recovered and purified as described in Example 1, for example using glutathione sepharose (for a GST-SGK fusion polypeptide), as described above and in Example 1.

In an embodiment of the above methods, the compound may act by interacting with the polypeptide of the invention and modulating, ie inhibiting or enhancing, its activation by, for example, PDK1 and/or a

preparation containing PDK2 activity or other activating protein kinase or protein kinases.

- It will be understood that it will be desirable to identify compounds that may modulate the activity of the polypeptide *in vivo*. Thus it will be understood that reagents and conditions used in the method may be chosen such that the interactions between the said SGK and its activating protein kinase or protein kinases are substantially the same as between human SGK and its activating protein kinase or protein kinases *in vivo*, which may be PDK1 and a polypeptide with PDK2 activity. Thus, it may be preferred that the activating protein kinase used in the assay is a physiological activating protein kinase of SGK, for example PDK1 or functional equivalent thereof and/or a preparation containing PDK2 activity for which interactions between the said SGK and the functional equivalent are substantially the same as between human SGK and the said physiological activating protein kinase. It will be appreciated that the compound may bind to the SGK or may bind to an activating protein kinase.
- By a functional equivalent of a physiological activating protein kinase of SGK, for example PDK1, is meant a protein kinase with substantially the same substrate specificity as the physiological activating protein kinase, for example PDK1 (ie capable of phosphorylating the underlined residue in the consensus sequence B-T-F-C-G-T-(P/T)-(D/E)-Y-(L/I/M)-A-P-E, where B is a basic residue), and/or capable of phosphorylating SGK on the same residue as the said physiological activating protein kinase.

It will be understood that it will be desirable to identify compounds that may modulate the activity of the polypeptide *in vivo*. Thus it will be

understood that reagents and conditions used in the method may be chosen such that the interactions between the said SGK and its substrate are substantially the same as between human SGK and its substrate or substrates *in vivo*. Thus, it may be preferred that the substrate used in the

5 assay is a physiological substrate of SGK or a fragment, variant, derivative or fusion thereof or fusion of a said fragment, variant or derivative (defined in an analogous manner to the definitions given above in relation to SGK) for which interactions between the said SGK and the

10 between human SGK and the said physiological substrate. An example of a substrate of SGK is GSK3.

Physiological substrates of SGK may include substrates identified, for example in overexpression studies referred to in Example 1, as

15 physiological substrates for PKB. The finding presented here concerning the activation and substrate specificity of SGK and its similarity to the activation and substrate specificity of PKB may indicate that substrates previously identified as physiological substrates for PKB may additionally or alternatively be physiological substrates for SGK.

20

PKB has been thought to mediate a number of the actions of insulin, including stimulation of glucose and amino acid uptake, glycogen and protein synthesis and cardiac muscle glycolysis (reviewed in [7, 8]) as well as regulation of the transcription of specific genes [9, 10]. Secondly,

25 the PKB β isoform is overexpressed in a significant percentage of ovarian and pancreatic cancers [11, 12] and the PKB α isoform in some breast cancers [2]. It appears that PKB or SGK may be capable of providing a survival signal that protects cells from apoptosis induced in a variety of ways (reviewed in [8, 13]). The activation of PKB or SGK by gene

amplification and other mechanisms may therefore contribute to the generation of malignancies that are able to flourish in the absence of extracellular survival signals.

- 5 PKB phosphorylates proteins and peptides at serine and threonine residues that lie in Arg-Xaa-Arg,-Xaa-Xaa-Ser/Thr- sequences [14]. In insulin signal transduction two physiological substrates of PKB appear to be the protein kinase -glycogen synthase kinase-3 (GSK3) [15, 16] and the cardiac isoform of phosphofructokinase-2 (PFK2) [8, 17].
- 10 Phosphorylation by PKB inhibits GSK3 activity leading to dephosphorylation and activation of glycogen synthase and protein synthesis initiation factor eIF2B [18]. We show here that SGK is as effective *in vitro* at inactivating GSK3 as PKB. However, factors including the relative levels of PKB and SGK detected in appropriate
- 15 tissues, suggest that PKB may be more important in the regulation of GSK3 than SGK.

- Dephosphorylation and activation of glycogen synthase and protein synthesis initiation factor eIF2B [18] may contribute to the insulin-induced
- 20 stimulation of glycogen synthesis and protein synthesis, respectively. PKB activates cardiac PFK2, which seems to underlie the insulin-induced stimulation of glycolysis in the heart. In the protection of cells against apoptosis, BAD appears to be one of the physiological substrates of PKB (and may therefore also be a physiological substrate of SGK). This
 - 25 protein, in its dephosphorylated form, interacts with the Bcl family member Bcl_{XL}, thereby inducing apoptosis in some cells. However, when PKB phosphorylates BAD at Ser136, it dissociates from Bcl_{XL}, interacts with 14-3-3 proteins instead, and apoptosis is prevented [19]. Thus, the

polypeptide BAD, which may be involved in control of apoptosis, may be a physiological substrate of SGK.

- 5 In one embodiment, the compound decreases the activity of said SGK polypeptide. For example, the compound may bind substantially reversibly or substantially irreversibly to the active site of said polypeptide. In a further example, the compound may bind to a portion of said polypeptide that is not the active site so as to interfere with the
- 10 binding of the said polypeptide to its substrate. In a still further example, the compound may bind to a portion of said polypeptide so as to decrease said polypeptide's activity by an allosteric effect. This allosteric effect may be an allosteric effect that is involved in the natural regulation of the said polypeptide's activity, for example in the activation of the said
- 15 polypeptide by an "upstream activator" such as PDK1 and/or PDK2 (or a preparation containing PKD2 activity).

- In a further embodiment, the compound increases the activity of said polypeptide. For example, the compound may bind to a portion of said
- 20 polypeptide that is not the active site so as to aid the binding of the said polypeptide to its substrate. In a still further example, the compound may bind to a portion of said polypeptide so as to increase said polypeptide's activity by an allosteric effect. This allosteric effect may be an allosteric effect that is involved in the natural regulation of the said polypeptide's
- 25 activity for example in the activation of the said polypeptide by an "upstream activator" such as PDK1 and/or PDK2 (or a preparation containing PDK2 activity).

Conveniently, the method makes use of the fact that SGK phosphorylates Crosstide as described in Example 1, but any suitable substrate, for example a physiological substrate of SGK, may be used. Thus the phosphorylation of Crosstide may be measured using techniques well known to those skilled in the art.

Conveniently, the method makes use of an assay which may be substantially the same as that described in Example 1. In Example 1, phosphorylation of Crosstide by SGK is measured. It is preferred that the SGK is recombinant SGK.

Alternatively, a change in the activity of the substrate may be measured. This may be done in a whole cell system or using purified or partially purified components. Thus, it will be appreciated that the phosphorylation of the substrate may be measured by measuring a change in the activity of the substrate. For example, the substrate may be GSK3 and the phosphorylation of GSK3 may be measured by measuring the activity of GSK3, as described in Example 1. It will be appreciated that it may be necessary to determine the effect of the compound on the activity of the substrate, for example by measuring the activity of the substrate when exposed to the compound (1) after exposure of the substrate to SGK, (2) before exposure of the substrate to SGK and/or (3) without exposure to SGK.

Similarly, expression of a protein encoded by an RNA transcribed from a promoter regulated (directly or indirectly) by a substrate of SGK may be measured. Expression of leptin may be affected by PKB (Barthel *et al* (1997) *Endocrinol* 183, 3559-3562) and/or SGK. The expression of the ob gene product leptin in adipose tissues has been previously described to

be regulated by insulin *in vivo* and *in vitro*. A constitutively active version of PKB induced production of leptin in 3T3-L1 adipocytes, possibly *via* a non-transcriptional mechanism. Leptin expression therefore may be controlled by PKB and/or SGK.

5

Expression of IGF-1 binding protein may be affected by PKB (Cichy *et al* (1998) *J Biol Chem* 273, 6482-6487). Expression of phosphoenolpyruvate
10 carboxykinase (PEPCK) may also be affected by PKB (Sutherland *et al* (1998) *J Biol Chem* 273, 3198-3204). The protein may be one that is physiologically regulated by a substrate of SGK or may be a "reporter" protein, as well known to those skilled in the art (ie a recombinant construct may be used). A reporter protein may be one whose activity
15 may easily be assayed, for example β -galactosidase, chloramphenicol acetyltransferase or luciferase (see, for example, Tan *et al* (1996)).

A still further aspect of the invention provides a method of identifying a compound which binds to a substrate, preferably a physiological substrate,
20 of SGK, as discussed above, which may be, for example, GSK3 or BAD, and either enhances or prevents its activation and/or phosphorylation by SGK, the method comprising determining whether a compound enhances or prevents the interaction of the said substrate with SGK or determining whether the compound substantially blocks phosphorylation and/or
25 activation of the said substrate by SGK.

Suitable assays may be similar to those described above.

A further aspect of the invention is a method of identifying a compound which modulates (for example, inhibits or enhances) the activation of SGK by an interacting polypeptide, preferably a physiological interacting polypeptide, as discussed above, such as PDK1 or a polypeptide with PDK2 activity (which may be present in a preparation containing PDK2 activity), the method comprising determining whether a compound enhances or disrupts the interaction between (a) SGK and (b) the interacting polypeptide, such as PDK1 or a preparation containing PDK2 activity or a functional equivalent of PDK1 or PDK2, or determining whether the compound modulates (for example, enhances, or inhibits, including substantially blocks) activation of the said SGK by the interacting polypeptide, such as PDK1 or a functional equivalent thereof or a preparation containing PDK2 activity or a functional equivalent thereof.

Expression of PDK1 is described in Example 1, in which references are also given which describe the sequence of PDK1.

A still further aspect of the invention provides a method of identifying a polypeptide that interacts with activated SGK, the method comprising (1) contacting (a) the said SGK with (b) a composition that may contain a polypeptide that interacts with the said activated SGK, (2) detecting the presence of a complex containing the said SGK and a polypeptide, and optionally (3) identifying any polypeptide bound to the said protein kinase.

In one embodiment, the composition may comprise material from cells. In particular, the cells may be selected from the following types: (1) cells which do not express SGK even when stimulated, (2) cells which express SGK after exposure to a stimulus, but which have not been so exposed, (3)

cells of type 2 after exposure to the stimulus and (4) cells of type 3 after exposure to a stimulus that activates SGK (for example exposure of 293 cells to hydrogen peroxide or IGF-1). Polypeptides that are found in a subset only of types 1-4 are of particular interest and may be characterised further. Such a polypeptide may be an activator of SGK. Alternatively, it may be an inactivator of SGK.

It will be appreciated that the method may be performed within a cell, for example using the yeast two hybrid system as is well known in the art. In this example, cDNAs copied from mRNA from the three cell types described above would be used.

It will further be appreciated that a transgenic animal in which a SGK gene is altered and/or a recombinant SGK gene is present, for example a rodent, in particular a mouse, may be useful in, for example, identifying a substrate of SGK. A said transgenic animal in which each SGK gene present is altered may be particularly useful. It will be appreciated that a said transgenic animal in which one or more, including all, PKB genes are also altered and/or a recombinant PKB gene is present may also be useful.

Conveniently, the SGK used in a method of the invention is one which is produced by recombinant DNA technology. Similarly, it is preferred if the PDK1 or other "upstream activator" used in the method is one which is produced by recombinant DNA technology. Similarly, it is preferred but not essential that the substrate, for example GSK3 or Crosstide, is produced by recombinant DNA technology or automated synthetic techniques, as well known to those skilled in the art. GSK3 may alternatively be purified from rabbit skeletal muscle (see Example 1 and references therein).

- It will be appreciated that it may be necessary to activate the SGK prior to its use in assays. In a preferred embodiment the SGK is activated *in vitro* by treating the polypeptide with PDK1 and MgATP, as described in
- 5 Example 1. Recombinant or endogenous SGK may be activated in a cell, for example a 293 cell, for example by stimulation of the cell with IGF-1 or hydrogen peroxide, as described in Example 1. It is particularly preferred if the SGK is the recombinant polypeptide produced according to the methods of the invention. It is still more preferred that the SGK is
- 10 SGK in which the residue equivalent to serine 422 of full-length human SGK is replaced by an aspartate residue and the residues equivalent to threonine 256 and lysine 127 of the full-length human SGK remain as threonine and lysine respectively.
- 15 It will be appreciated that by "suitable" we mean that the said components in the method are those that have interactions or activities which are substantially the same as those of SGK or a physiological substrate of SGK or Crosstide or GSK3 or other substrates, or the upstream activator such as PDK1 as the case may be but which may be more convenient to use in
- 20 an assay. For example, fusions of SGK and PDK1 are particularly useful since said fusion may contain a moiety which may allow the fusion to be purified readily.

- It will be appreciated that the methods described may be performed in
- 25 cells. "Reporter gene" constructs may be prepared by methods known to those skilled in the art, using the teaching herein. For example, a reporter gene construct may be made with a leptin gene promoter sequence or IGF-1 binding protein gene promoter sequence or other PKB and/or SGK-dependent promoter sequence. This construct may be introduced together

with an SGK construct into a cell line, in the parent cell line of which leptin is activated in response to known stimuli, and in which the endogenous SGK gene or genes (and optionally the PKB gene or genes) have been inactivated. Alternatively the reporter gene construct could be introduced into the cell line in which SGK and a substrate of SGK is activated in response to known stimuli. The expression of the reporter gene will be dependent on the activity of SGK and thus the effect of compounds can be measured. In a further example, the reporter gene may be fatal to the cells, or alternatively may allow cells to survive under otherwise fatal conditions. Cell survival can then be measured, for example using colorimetric assays for mitochondrial activity, such as reduction of WST-1 (Boehringer). WST-1 is a formosan dye that undergoes a change in absorbance on receiving electrons *via* succinate dehydrogenase. In a further embodiment the yeast two-hybrid system is used.

The enhancement or disruption of the interaction between SGK and an interacting polypeptide as defined above, or suitable derivatives, fragments, fusions or variants can be measured *in vitro* using methods well known in the art of biochemistry and include any methods which can be used to assess protein-protein interactions.

The said interaction can also be measured within a cell, for example using the yeast two hybrid system as is well known in the art.

It will be appreciated that the invention provides screening assays for drugs which may be useful in modulating, for example either enhancing or inhibiting, the activity of SGK or its interactions with upstream activators. The compounds identified in the methods may themselves be useful as a

drug or they may represent lead compounds for the design and synthesis of more efficacious compounds.

5 It will be appreciated that screening assays which are capable of high throughput operation will be particularly preferred. Examples may include the cell based assays described and protein-protein binding assays. A further example is an SPA-based (Scintillation Proximity Assay) system as described in Example 2.

10 The compound may be a drug-like compound or lead compound for the development of a drug-like compound for each of the above methods of identifying a compound. It will be appreciated that the said methods may be useful as screening assays in the development of pharmaceutical compounds or drugs, as well known to those skilled in the art.

15 The term "drug-like compound" is well known to those skilled in the art, and may include the meaning of a compound that has characteristics that may make it suitable for use in medicine, for example as the active ingredient in a medicament. Thus, for example, a drug-like compound
20 may be a molecule that may be synthesised by the techniques of organic chemistry, less preferably by techniques of molecular biology or biochemistry, and is preferably a small molecule, which may be of less than 5000 daltons and which may be water-soluble. A drug-like compound may additionally exhibit features of selective interaction with a
25 particular protein or proteins and be bioavailable and/or able to penetrate target cellular membranes, but it will be appreciated that these features are not essential.

The term "lead compound" is similarly well known to those skilled in the art, and may include the meaning that the compound, whilst not itself suitable for use as a drug (for example because it is only weakly potent against its intended target, non-selective in its action, unstable, poorly soluble, difficult to synthesise or has poor bioavailability) may provide a starting-point for the design of other compounds that may have more desirable characteristics.

- It will be appreciated that screening assays which are capable of high throughput operation will be particularly preferred. Examples may include cell based assays and protein-protein binding assays. An SPA-based (Scintillation Proximity Assay; Amersham International) system may be used. For example, beads comprising scintillant and a substrate polypeptide, for example Crosstide or a peptide comprising the amino acid sequence of Crosstide may be prepared. The beads may be mixed with a sample comprising ^{32}P - or ^{33}P - γ -labelled ATP, SGK (as defined above) and with the test compound. Conveniently this is done in a 96-well format. The plate is then counted using a suitable scintillation counter, using known parameters for ^{32}P or ^{33}P SPA assays. Only ^{32}P or ^{33}P that is in proximity to the scintillant, i.e. only that bound to Crosstide that is bound to the beads, is detected. Variants of such an assay, for example in which the substrate polypeptide is immobilised on the scintillant beads *via* binding to an antibody or antibody fragment, may also be used.
- Other methods of detecting polypeptide/polypeptide interactions include ultrafiltration with ion spray mass spectroscopy/HPLC methods or other physical and analytical methods. Fluorescence Energy Resonance Transfer (FRET) methods, for example, well known to those skilled in the art, may be used, in which binding of two fluorescent labelled entities may

be measured by measuring the interaction of the fluorescent labels when in close proximity to each other.

5 A further aspect of the invention is a kit of parts useful in carrying out a method, for example a screening method, of the invention. Such a kit may comprise SGK (as defined above), PDK1 or a functional equivalent thereof or a preparation containing PDK2 activity or a functional equivalent thereof and/or a substrate of SGK, for example Crosstide or GSK3 or BAD.

10

A further aspect of the invention is a compound identifiable or identified by a method of the invention.

15 It is preferred that a compound of the invention does not modulate the activity or activation of PKB, for example PKB α , or of PDK1. Thus, it may be desirable to assess the effect of any compound identified by a screening method of the invention on the activity or activation of PKB, for example PKB α , or PDK1. Methods of assessing the effect of any compound on the activity or activation of PKB will be known to the person skilled in the art and may be similar to the methods described
20 herein for assessing the effect of any compound on the activity or activation of SGK, with the substitution of PKB or suitable variant, fragment derivative or fusion or fusion of a suitable variant, fragment or derivative, as defined in an analogous manner to SGK, above, for SGK.

25

A further aspect of the invention is a method of identifying a substrate of SGK wherein a compound that modulates the activity of, for example inhibits, SGK but does not modulate the activity of, for example inhibit PKB, for example PKB α is used. For example, the method may be a

method in which the effect of a compound that inhibits SGK but does not inhibit PDK1 on cellular metabolism is assessed. Thus, for example, the effect of such a compound on signalling events thought to be mediated by activation of PKB α may be assessed, as discussed in Example 1. It will be appreciated that such a method may be carried out in whole cells or on partially or semi-purified cellular components. Alternatively, a compound that modulates the activity of, for example inhibits, PKB, for example PKB α but does not modulate the activity of, for example inhibit SGK, for may be used in a method of identifying a substrate of SKG in a similar manner to that described above.

A still further aspect of the invention is a compound identifiable or identified by a method of the invention for use in medicine.

A further aspect of the invention is the use of a compound identifiable or identified by a method of the invention in the manufacture of a medicament for treatment of a patient in need of modulation of the activity of SGK.

It is preferred that the patient is mammalian. It is further preferred that the patient is human.

A compound that is capable of reducing the activity of SGK may be useful in treating cancer. PKB and/or SGK may be capable of providing a survival signal that protects cells from apoptosis induced in a variety of ways (reviewed in [8, 13]). Thus, such compounds may aid apoptosis. Reduction of the activity of SGK may promote apoptosis and may therefore be useful in treating cancer. Conditions in which aiding apoptosis may be of benefit may also include resolution of inflammation.

5 A compound is capable of increasing the activity of SGK may be useful in treating diabetes or obesity, or may be useful in inhibiting apoptosis. Increased activity of PKB and/or SGK may lead to increased levels of leptin, as discussed above, which may lead to weight loss; thus such compounds may lead to weight loss. For example, such compounds may suppress apoptosis, which may aid cell survival during or following cell damaging processes. It is believed that such compounds are useful in treating disease in which apoptosis is involved. Examples of such diseases include, but are not limited to, mechanical (including heat) tissue injury or ischaemic disease, for example stroke and myocardial infarction, neural injury and myocardial infarction. Thus the patient in need of modulation of the activity of SGK may be a patient with cancer or with diabetes, or a patient in need of inhibition of apoptosis, for example a patient suffering from tissue injury or ischaemic injury, including stroke.

20 Thus, a further aspect of the invention provides a method of treating a patient with an ischaemic disease the method comprising administering to the patient an effective amount of a compound identifiable by the screening methods of the invention.

25 A still further invention provides a use of a compound identifiable by the screening methods of the invention in the manufacture of a medicament for treating an ischaemic disease in a patient.

Thus, a further aspect of the invention provides a method of treating a patient with an ischaemic disease the method comprising administering to the patient an effective amount of a compound identifiable by the screening methods of the invention.

If the patient is a patient in need of promotion of apoptosis, for example a patient with cancer, it is preferred that the compound of the invention that is used in the preparation of the medicament is capable of reducing the activity of SGK. If the patient is a patient with diabetes or a patient in need of inhibition of apoptosis, for example a patient with ischaemic disease, it is preferred that the compound of the invention that is used in the preparation of the medicament is capable of increasing the activity of SGK.

10

The aforementioned compounds of the invention or a formulation thereof may be administered by any conventional method including oral and parenteral (e.g. subcutaneous or intramuscular) injection. The treatment may consist of a single dose or a plurality of doses over a period of time.

15

Whilst it is possible for a compound of the invention to be administered alone, it is preferable to present it as a pharmaceutical formulation, together with one or more acceptable carriers. The carrier(s) must be "acceptable" in the sense of being compatible with the compound of the invention and not deleterious to the recipients thereof. Typically, the carriers will be water or saline which will be sterile and pyrogen free.

20

Thus, the invention also provides pharmaceutical compositions comprising the compound identifiable by the screening methods of the invention and a pharmaceutically acceptable carrier.

25

Figure Legends.

Fig. 1.

Amino acid sequences surrounding the activating phosphorylation sites on PKB, p70 S6 kinase and PKC ξ and their similarity to the corresponding regions of SGK. Identities are shown in boldface type and the phosphorylated residues in PKB and p70 S6 kinase are underlined. The phosphorylation sites are separated by 160-165 residues in each enzyme.

Fig. 2. Expression and purification of SGK and PKB fusion proteins in 293 cells. GST fusion proteins expressed in 293 cells were purified on glutathione-Sepharose from 200 μ g of cell lysate protein, subjected to electrophoresis on 5-20% (panel A) or 10% (panel B) SDS-polyacrylamide gels and stained with Coomassie Blue. Cells were transfected with the following constructs:- Lane 1, pEBG2T expressing GST; lanes 2 and 4, PEBG-SGK expressing full length SGK; lane 3, pEBG-PKB α expressing full length PKB α ; lane 5 pEBG- Δ N-SGK(61-431) expressing the N-terminally truncated form of SGK. The marker proteins (lanes M) and their molecular masses are also shown.

Fig. 3. Activity of GST-SGK fusion proteins purified from unstimulated 293 cells. Wild type SGK and the mutants indicated were expressed in 293 cells and purified on glutathione-Sepharose. Each fusion protein (1 μ g) was incubated for 20 min at 30°C with protein phosphatase 2A (30 mU / ml) in 50 μ l of 50 mM Tris/HCl pH 7.5, 0.1 mM EGTA, 0.1 % (v/v) 2-mercaptoethanol. Where indicated (+), microcystin-LR (1 μ M) was included prior to the addition of PP2A. In the other incubations (-) microcystin-LR was only added after treatment with the phosphatase. SGK activity was then measured using "Crosstide" as substrate.

Fig. 4. Phosphorylation and activation and of SGK by PDK1 *in vitro*

(A) GST-SGK (0.3 μ g) was phosphorylated using GST-PDK1 (0.1 μ g) and [γ - 32 P] ATP (500 cpm / pmol) as described under Methods. Where indicated (+), 1 μ M PtdIns(3,4,5)P₃ in lipid vesicles containing phosphatidylserine (100 μ M) and phosphatidylcholine (100 μ M) (PS/PC) were also included. The reactions were stopped by the addition of SDS to 2% and, after heating for 5 min at 95°C, the samples were subjected to electrophoresis on 10% SDS/polyacrylamide gels, stained with Coomassie blue and then autoradiographed. The positions of the molecular mass markers are also indicated (B) Same as (A), except that unlabelled ATP was used instead of [γ - 32 P] ATP. After incubation for 10 min at 30°C, 10 μ l aliquots were assayed for SGK activity using Crosstide as substrate. The results are shown \pm SD for three separate experiments.

Fig.5. Effect of mutations on the phosphorylation of SGK by PDK1 *in vitro*. (A) GST fusion proteins of wild type (WT) or mutant SGK (0.3 μ g) were incubated with PP2A as described in the legend to Fig 3 and, after the addition of microcystin-LR (1 μ M) to inactivate the PP2A, the SGK proteins were incubated with [γ - 32 P]ATP (500 cpm/pmol) with (+) and without (-) PDK1 (0.1 μ g), subjected to SDS-PAGE, stained with Coomassie blue and then autoradiographed. The Lys 127Ala mutation creates a catalytically inactive mutant. (B) Same as (A), except that unlabelled ATP was used instead of [γ - 32 P] ATP (500 cpm/pmol). After incubation for 10 min at 30 °C, 10 μ l aliquots were assayed for SGK activity using Crosstide as substrate. The results are shown \pm SD for three separate experiments. (C) GST fusion proteins of wild type SGK or the S422D mutant (1 μ g) were incubated with PP2A and phosphorylated with PDK1 (0.2 μ g) and [γ - 32 P]ATP as in A, then subjected to SDS-PAGE

followed by autoradiography. (D) Same as (C), except that unlabelled ATP was used instead of $[\gamma\text{-}^{32}\text{P}]\text{ATP}$. After incubation for 10 min at 30°C, aliquots of the reactions were assayed for SGK activity. The results are shown \pm SD for three separate experiments.

5

Fig. 6. Mapping the PDK1 phosphorylation site on SGK (A) GST- ΔN -SGK[S422D] (26 μg) was phosphorylated with PDK1 and digested with V8 protease as described under Methods. The digest was applied to a Vydac C18 column equilibrated in 0.1 % (v/v) trifluoroacetic acid (TFA). The column was developed with a linear gradient of acetonitrile in 0.1 % TFA at a flow rate of 0.8 ml / min and fractions of 0.4 ml were collected. ^{32}P -radioactivity is shown by the full line and the acetonitrile gradient by the diagonal line. The inset shows phosphoamino acid analysis of the major ^{32}P -labelled peptide. (B) An aliquot of the major phosphopeptide in panel A was analysed by solid-phase sequencing on an Applied Biosystems 470A sequencer [29] and ^{32}P -radioactivity released after each cycle of Edman degradation was measured.

10

15

Fig. 7. SGK and PKB α inactivate GSK3 at similar rates.

The incubations were carried out as described for peptide phosphorylation, except that GSK3 (50mU) purified from rabbit skeletal muscle replaced the peptide. Units of GSK3 activity are defined in [30]. At various times after incubation with MgATP alone (open triangles) and either SGK (open circles) or PKB α (closed circles) aliquots were removed and assayed for GSK3 activity as in [30].

25

Fig. 8. Activation of SGK in 293 cells.

(A) Cells were transiently transfected with DNA constructs expressing wild type GST-SGK (SGK-WT) or GST-SGK[T256A], then stimulated for

- 10 min with 50 ng /ml IGF-1 or 25 min with 2 mM hydrogen peroxide, followed by lysis in ice-cold lysis buffer. 5 μ l of glutathione Sepharose were added to 50 mg of cell lysate protein and after end over end rotation for 30 min at 40°C, the suspension was centrifuged for 1 min at 13,000 x g. The supernatant was discarded and the beads washed four times with 1 ml of Buffer A containing 0.5 M NaCl, then three times with Buffer B. 40 μ l of 60mM Tris/HCl pH 7.5, 0.12 mM EGTA, 0.12% (v/v) 2-mercaptoethanol, 3.0 μ M PKI, 1.2 μ M microcystin-LR, 12 mM magnesium chloride and 36 μ M "Crosstide" was added to the beads.
- 10 After leaving on ice for 10 min, the beads were assayed for SGK activity at 30°C by the addition of 5 μ l of 1 mM [γ - 32 P] ATP (500 cpm/pmol). The expression of wild-type and mutants SGKs in 293 cells were similar as judged by SDS/polyacrylamide gel electrophoresis followed by staining with Coomassie blue (data not shown). The results are presented \pm S.D.
- 15 for three separate experiments. (B) The experiment was carried with wild-type GST-SGK (SGK-WT) as in (A), except that the cells were pretreated for 10 min with 100 nM wortmannin before stimulation with IGF-1 or hydrogen peroxide.
- 20 **Fig. 9. Time course of activation of SGK in 293 cells.**
293 cells were transiently transfected with pEBG-SGK (open circles) or pEBG-PKB α (closed circles) then stimulated with 50 ng / ml IGF-1 (A) or 2 mM hydrogen peroxide (B). At the times indicated, the cells were lysed and the GST-SGK or GST-PKB α purified on glutathione Sepharose as in
- 25 Fig 8 and assayed. The open triangle shows the GST-SGK activity after incubation with PP2A (30 mU/ ml) as described in the legend to Fig 3. The results are presented \pm S.D. for a single experiment in which three separate dishes of cells were used at each time point. Similar results were obtained in another independent experiment.

Fig. 10. Effect of mutations at Ser422 on the activation of SGK in 293 cells (A) 293 cells were transiently transfected with pEBG-SGK, pEBG-SGK[S422A] or pEBG-SGK[S422D] and then stimulated for 10 min with (+) or without (-) 50 ng/ml IGF-1. The cells were lysed and the GST-SGKs purified on glutathione-Sepharose as in Fig 8 and assayed. 50 µg of cell lysate protein was used for the assay of wild type, SGK and SGK[S422A] and 25 µg for SGK[S422D]. Each protein was expressed in similar amounts as judged from SDS polyacrylamide gel electrophoresis followed by staining with Coomassie blue (data not shown). (B, C) Same as A except that the 293 cells were transiently transfected with pEBG-SGK (B) or pEBG-ΔN-SGK (C) as indicated and stimulated for 10 min with 50 ng/ml IGF-1. 50 µg of cell lysate protein was used for the assays of wild type SGK and 10 µg for the assays of the N-terminally truncated enzyme.

Example 1:

Activation of SGK by agonists that activate phosphatidylinositide 3-kinase is mediated by PDK1 and PDK2.

Summary. The PtdIns(3,4,5)P₃-dependent activation of protein kinase B (PKB) by 3-phosphoinositide-dependent protein kinases-1 and 2 (PDK1, PDK2) is a key event in mediating the effects of signals that activate PtdIns 3-kinase. Serum and glucocorticoid-induced protein kinase (SGK) is most similar to PKB (54% identity in the catalytic domain) and, although it lacks the PtdIns(3,4,5)P₃-binding pleckstrin-homology (PH) domain, it retains the residues in PKB that are phosphorylated by PDK1 (Thr308) and PDK2 (Ser473). Here we show that, like PKB, SGK is activated via a PtdIns 3-kinase-dependent pathway when 293 cells are stimulated with insulin-like growth factor-1 (IGF-1) or exposed to

hydrogen peroxide. Consistent with this finding, PDK1 activates SGK in vitro by phosphorylating Thr256, the residue equivalent to Thr308 of PKB, but the rate of activation is unaffected by PtdIns(3,4,5)P₃. However, the PDK1-induced activation of SGK *in vitro* is greatly

5 potentiated by the mutation of Ser422 to Asp (the residue equivalent to Ser473 of PKB). Consistent with this finding, SGK[Ser422Asp] expressed in 293 cells is fully activated by phosphorylation even in unstimulated cells, and this activation is unaffected by inhibitors of PtdIns 3-kinase. In contrast to PKB, the mutation of Ser422 does not by itself induce any

10 activation of SGK and mutation of Thr256 to Asp abolishes activation. Our results are consistent with a model in which the activation of SGK by IGF1 or hydrogen peroxide is initiated by the PtdIns(3,4,5)P₃-dependent activation of PDK2 which phosphorylates Ser422. This is then followed by the PtdIns(3,4,5)P₃-independent phosphorylation at Thr256, catalysed

15 by PDK1, which activates SGK. Like PKB, SGK preferentially phosphorylates serine and threonine residues that lie in Arg-Xaa-Arg-Xaa-Xaa-(Ser/Thr)- motifs, and SGK and PKB inactivated glycogen synthase kinase-3 (GSK-3) at similar rates *in vitro*. These findings raise the possibility that some physiological roles ascribed to PKB based on the

20 overexpression of constitutively active PKB mutants, may be mediated by SGK.

Materials and Methods

25 **Materials.** Human PDK1 was expressed as a glutathione-S-transferase (GST) fusion protein in 293 cells and purified on glutathione-Sepharose [9]. V8 protease (protease Glu-C) and complete protease inhibitor cocktail were purchased from Boehringer Mannheim. Residues 5-24 of the specific protein inhibitor of cAMP-dependent protein kinase (PKI) and all

other peptides were synthesised at the Department of MRC Protein Phosphorylation Unit, University of Dundee, by Mr. F.B. Caudwell. Sources of other materials are given in [6].

- 5 **Buffer solutions.** Buffer A was 50 mM Tris/HCl pH 7.5, 1 mM EDTA, 1 mM EGTA, 1 % (w/v) Triton X-100, 1 mM sodium orthovanadate, 50 mM NaF, 5 mM sodium pyrophosphate, 0.27 M sucrose, 0.1 % (v/v) 2-mercaptoethanol. Lysis buffer was Buffer A containing 1 μ M microcystin-LR, plus complete protease inhibitor cocktail (one tablet /
- 10 50ml) . Buffer B was 50 mM Tris/HCl pH 7.5, 1 mM EGTA, 0.1 % (v/v) 2-mercaptoethanol.

- Plasmids expressing SGK and site-directed mutagenesis.** A full length cDNA encoding human SGK from an infant brain library was obtained
- 15 from I.M.A.G.E. Consortium (clone ID 42669) and modified by PCR amplification to introduce a BamHI site at the 5' end (in frame with the GST sequence of the pEBG2T vector) and a KpnI site at the 3' end using, oligonucleotides 5'-ACA CGG ATC CGC CAC CAT GTA TCC ATA TGA TGT TCC AGA TTA TGC TAC GGT GAA AAC TGA GGC TGC
- 20 TAA GGG C-3' and 5'-ACA CGG TAC CGT CGA CTC AGA GGA AAG AGT CCG TGG GAG G-3'. The PCR product was digested with BamHI and KpnI and inserted into the cloning site of pEBG-2T. A truncated form of SGK (Δ N-SGK) lacking the N-terminal 60 residues was
- 25 obtained by removing the fragment between the BamHI site at the 5' of the cDNA and a BglII site located 175bp from the initiation codon, followed by religation after filling the gap with Klenow fragment. All of the point mutations in the SGK gene were introduced by *in vitro* mutagenesis using PCR.

Expression of SGK in 293 cells.

Cells were transfected with 10 μ g (10 cm dish) or 3 μ g (6 cm dish) of the pEBG-SGK constructs using a modified calcium phosphate gel method [6]. At 24 h after transfection, the cells were deprived of serum for 16 h, then

5 incubated for 10 min with or without 100 nM wortmannin or for 1 h with or without other inhibitors, followed by stimulation with 50 ng/ml IGF-1 or 2 mM hydrogen peroxide. The cells were lysed in 1ml of ice-cold lysis buffer, centrifuged for 5 min at 13,000 g and GST-SGK was purified on glutathione-Sepharose as described for PKB [6]. The glutathione-

10 Sepharose eluate was stored in aliquots at -80°C.

Phosphorylation and assay of SGK. Phosphorylation was carried out at 30°C in 50 μ l incubations containing 50 mM Tris/HCl pH 7.5, 0.1 mM EGTA, 0.1% (v/v) 2-mercaptoethanol, 2.5 μ M PKI, 1 μ M microcystin-

15 LR, 10 mM magnesium chloride and 100 μ M ATP. Where indicated lipid vesicles containing phosphatidylcholine (100 μ M), phosphatidyl serine (100 μ M) and PtdIns(3,4,5)P₃ (1 μ M) were also included. SGK activity was assayed exactly as described for PKB [6] using the peptide GRPRTSSFAEG ("Crosstide") at 30 μ M as substrate. One unit of

20 activity (U) was that amount which catalysed the phosphorylation of 1 nmole of Crosstide in one min.

Mapping the site on SGK phosphorylated by PDK1. The N-terminally truncated SGK in which Ser422 had been mutated to Asp (GST- Δ N-SGK[S422D]) (26 μ g) was incubated for 20 min at 30°C with PP2A (30

25 mU/ml), where one unit of activity is that amount which catalyses the dephosphorylation of 1 nmole of phosphorylase α in one min. After addition of microcystin-LR to 1 μ M to inactivate PP2A, the SGK was

phosphorylated by incubation for 30 min at 30°C with GST-PDK1 (2 µg) and [γ - 32 P]ATP (5,000 cpm/pmol). The reaction was stopped after 30 min by adding SDS and 2-mercaptoethanol to final concentrations of 1 % (w/v) and 1 % (v/v), respectively, followed by heating at 95°C for 5 min. The sample was then incubated for 1 h at 30°C with 2 % (v/v) 4-vinylpyridine to alkylate cysteine residues, electrophoresed on a 10% SDS/polyacrylamide gel, and the 32 P-labelled SGK was eluted from the gel and precipitated by the addition of trichloroacetic acid to 20 % (w/v). The precipitated protein was washed six times with 0.2 ml of water, resuspended in 0.3 ml of 50 mM NH_4HCO_3 (pH 7.8), digested for 18h with V8 protease (1 µg) and then chromatographed on a Vydac C18 column as described under Results. Peptide fractions were analysed on a Perceptive Biosystems (Framingham, MA) Elite STR MALDI-TOF mass spectrometer in the linear and relectron mode, using 10 mg/ml α -cyanocinnamic acid as the matrix. Phosphoamino acid analysis was carried out as described in [26].

Results

20 Expression of SGK in 293 cells.

Initial attempts to express SGK with a haemagglutinin tag at its N-terminus were unsuccessful because the expressed protein was insoluble. The work reported in this example was therefore carried out using GST-fusion proteins, which were soluble when expressed in 293 cells. Full length GST-SGK (Fig 2A, lane 2) was expressed in 293 cells at a much lower level than GST-PKB α (Fig 2A, lane 3). This low level of expression appears to be due to the N-terminal 60 residues of SGK, because their removal increased the level of expression 50-250 fold (Fig 2B, lanes 4 and 5). 10-50 µg of 20% pure full length SGK and 0.5 mg of

80% pure Δ N-SKG(61-431) was usually obtained from 10, 10 cm diameter dishes of cells.

Phosphorylation and activation of wild type SGK by PDK1 in vitro.

- 5 The activity of GST-SGK purified from 293 cells was decreased by 70% following incubation with protein phosphatase 2A (PP2A) (Fig 3), a serine/threonine-specific phosphatase, and inactivation was prevented by microcystin, a specific PP2A inhibitor [27]. Thus, the basal activity of SGK results from its phosphorylation at one or more serine/threonine
- 10 residues.

- GST-SGK could be phosphorylated by PDK1 (Fig 4A) and phosphorylation was accompanied by a 10-fold increase in the basal activity (Fig 4B). Almost the same level of activity was attained if GST-SGK was first
- 15 inactivated by treatment with PP2A and then phosphorylated with PDK1 (data not shown). However, PDK1 phosphorylated GST-SGK much more slowly than PKB α and the maximal stoichiometry of phosphorylation that could be attained was 0.05 mol/mol, compared to 0.5 mol/mol for PKB α . Moreover, unlike the activation of PKB α , the phosphorylation (Fig 4A)
 - 20 and activation (Fig 4B) of SGK was unaffected by PtdIns(3,4,5)P₃ in the presence (Fig 4) or absence (data not shown) of lipid vesicles containing phosphatidylserine and phosphatidylcholine.

Effect of mutation of Ser422 and Thr256 on the activity of SGK.

- 25 PKB α can be partially activated (5-fold) by mutation of Thr308 to Asp or by mutation of Ser473 to Asp, and almost fully activated (20-fold) when both mutations are combined. It was therefore of interest to study the effect of the equivalent mutations on the activity of SGK.

GST-SGK[T256D], GST-SGK[T256E] or GST-SGK[T256A] purified from transfected 293 cells were all much less active than wild-type SGK, the activities being similar to wild-type SGK that had been treated with PP2A (Fig 3). In contrast, GST-SGK(S422D) purified from 293 cells had a specific activity more than ten-fold higher than that of the wild-type enzyme (Fig 3). However, the activity of GST-SGK(S422D) did not result from the mutation of Ser422 to Asp *per se* but from increased phosphorylation, because it could be reduced to the same level as GST-SGK[T256D] or GST-SGK[T256A] by incubation with PP2A (Fig 2).

GST-SGK[S422A] purified from 293 cells also had very low activity, similar to GST-SGK[T256A] or the wild-type enzyme after treatment with PP2A.

Effect of mutation of Ser422 or Thr256 on the phosphorylation of SGK by PDK1 in vitro

The mutation of Ser422 to Ala did not affect the extent of phosphorylation of SGK by PDK1 (Fig 5A), but reduced the extent of activation by 60% (Fig 5B). In contrast, the mutation of Thr256 to Ala (or mutation of both Thr256 and Ser422 to Ala) reduced phosphorylation by 80-90% (Fig 5A) and abolished activation by PDK1 (Fig 5B).

The mutation of Ser422 to Asp stimulated the rate of phosphorylation (Fig 5C) and activation (Fig 5D) by PDK1 at least six-fold. In contrast, the GST-SGK[T256A/S422D] double mutant was not activated at all by PDK1 and phosphorylation by PDK1 was reduced by 80-90% (data not shown).

We also mutated Lys 127 in the ATP binding site to Ala to create a "kinase dead" protein. This mutant was phosphorylated at the same rate, and to the same extent, as wild type SGK (Fig 5A) and, as expected, could not be activated by PDK1 (Fig 5B).

5

Identification of Thr256 as the residue on SGK phosphorylated by PDK1 in vitro.

The results described above suggested that the activation of SGK by PDK1 was likely to result from the phosphorylation of Thr256. In order to investigate whether this was so, we used a form of SGK that was truncated at its N-terminus (GST-ΔN-SGK[61-431]) because this mutant was expressed at far higher levels than the wild type enzyme, and Ser422 was also mutated to Asp to facilitate phosphorylation by PDK1. Like GST-SGK[S422D] (Fig 3), GST-ΔN-SGK(61-431)[S422D] purified from 293 cells had a high activity, which could be virtually abolished by treatment with PP2A (data not shown).

PP2A-treated GST-ΔN-SGK[S422D] was phosphorylated by PDK1 to a stoichiometry of 0.6 mol/mol protein, and the ³²P-labelled enzyme digested with V8 protease and chromatographed on a C18 column. One major peak and several minor peaks of ³²P radioactivity were observed as shown in Fig 6A. Analysis of the major peak by MALDI-TOF mass spectroscopy showed that its molecular mass (1923.15) was identical to that expected for the peptide comprising residues 247-262 of SGK (NEEHNSTTSTFCGTPE) containing one phosphorylated residue. Residue 247 is preceded by glutamic acid, as expected from the specificity of V8 protease. Phosphoamino acid analysis indicated that this peptide contained phosphothreonine only (inset to Fig 6A). When this phosphopeptide was subjected to solid phase sequencing, ³²P-radioactivity

was released after the 10th cycle of Edman degradation corresponding to Thr256 (Fig 6B). These results, together with those obtained using the Ser256Ala mutant (Fig 5A) indicate that SGK is phosphorylated by PDK1 at Thr256, the equivalent residue to Thr308 of PKB α .

5

Substrate specificity of SGK. We compared the substrate specificities of SGK and PKB α towards several synthetic peptides related to "Crosstide" (Table 1). Like PKB α , SGK had an absolute requirement for an arginine residue five residues N-terminal to the site of phosphorylation since mutation, even to another basic amino acid (Lys), almost abolished activity. The presence of an Arg three residues N-terminal to the site of phosphorylation was also important, but not quite as critical as for PKB α . Like PKB α , SGK required at least one residue C-terminal to the phosphorylation site and a hydrophobic residue was strongly preferred at this position, though not as critical as for PKB α . Another significant difference between PKB α and SGK was that the latter was more tolerant of the substitution of serine by threonine at the site of phosphorylation. Although the results presented in Table 1 were carried out using PDK1-activated GST- Δ N-SGK[S422D], similar results were obtained with full length SGK.

20

Glycogen synthase kinase-3 (GSK-3) is a protein thought to be a physiological substrate for PKB [28]. When PKB α and SGK were matched for activity towards Crosstide, both enzymes inactivated GSK3 at similar rates (Fig 7).

25

Activation of SGK in 293 cells by extracellular signals.

PKB is activated in 293 cells in response to agonists that activate PtdIns 3-kinase, such as insulin or IGF-1 or certain adverse stimuli (heat shock,

oxidative stress). Since the activation of PKB results from the phosphorylation of Thr308 and Ser473, and these residues and the sequences surrounding them are highly conserved in SGK (Fig 1), we investigated whether SGK could be activated by these and/or other signals in 293 cells.

Cells overexpressing GST-SGK were stimulated with IGF-1 or exposed to hydrogen peroxide, which induced a 2.5-4-fold activation (Figs 8A and 8B). Activation was strongly suppressed if the cells were first pre-incubated with the PtdIns 3-kinase inhibitor wortmannin (Fig 8B). In contrast, the immunosuppressant drug rapamycin that prevents the activation of p70 S6 kinase, had no effect on the activation of SGK (data not shown). SGK[T256A] could not be activated by either IGF-1 or hydrogen peroxide.

The IGF-1 and hydrogen peroxide-induced activation was caused by increased phosphorylation because, like the basal activity, the stimulated activity was abolished by treatment with PP2A (Fig 9). In addition activation by these stimuli was not observed when SGK[T256A] was transfected instead of wild-type SGK (Fig 8A). The activation of GSTSGK induced by IGF-1 or hydrogen peroxide was slightly slower than activation of GST-PKB α under the same conditions (Fig 9).

Phorbol myristate acetate (400 ng / ml, 30 min) or EGF (100 ng / ml, 30 min), which are much stronger activators of the classical mitogen-activated protein (MAP) kinase cascade in 293 cells than IGF-1, did not induce any activation of SGK (data not shown).

Activation of SGK mutants by IGF-1.

The activity of GST-SGK[S422D] was high in 293 cells that had not been stimulated with IGF-1 (Fig 3) and, interestingly, could not be activated further by IGF-1 (Fig 10A). Moreover, preincubation of 293 cells with 100 nM wortmannin (30 min) did not affect the high basal activity of SGK (data not shown). In contrast, GST-SGK[S422A] had very low activity in 293 cells that was not increased by IGF-1 (Fig 10A).

GST-ΔN-SGK was activated similarly to full-length wild-type SGK in response to IGF-1 (Figs 10B and 10C), indicating that the N-terminal non-catalytic domain is not required for activation in 293 cells.

Discussion.

Although it is well established that SGK is the product of an immediate early gene whose levels increase within a hour in response to several agonists and pathological conditions (see Introduction), the possibility that SGK is also regulated by reversible phosphorylation has not been investigated previously. In this example, we establish that the activity of SGK expressed in 293 cells is determined by its level of phosphorylation (Fig 3) which increases within minutes in response to signals that activate PtdIns 3-kinase (Figs 8 and 9). We have also provided evidence that the key phosphorylation sites on SGK are Thr256 and Ser422, the residues equivalent to those on PKBα that are targeted by PDK1 and PDK2, respectively.

SGK is phosphorylated and activated by PDK1 *in vitro* (Fig 4) and the major site of phosphorylation is Thr256 (Fig 6). Activation is abolished, and phosphorylation greatly reduced, if Thr256 is mutated to Ala (Fig 5). Thus the PDK1-induced activation of SGK is mediated by the phosphorylation of Thr256. However, the effects of phosphorylation

could not be mimicked by mutating Thr256 to an acidic residue, and such mutations actually reduced activity to the level of the PP2A-treated wild-type enzyme (Fig 3). This is similar to observations made with p70 S6 kinase [28], but is in contrast to PKB α where mutation of Thr308 to Asp causes partial activation of the enzyme [6]. The finding that phosphorylation of SGK by PDK1 is not totally abolished if Thr256 is mutated to Ala (Fig 4) indicates that PDK1 is capable of phosphorylating another site(s) on GST-SGK[T256A] *in vitro*, but the identity of this site and its relevance (if any) to the activation process remains to be evaluated. The Thr308Ala mutant of PKB α (but not the wild-type enzyme) is phosphorylated at Thr304 by PDK1 *in vitro* without causing any activation (results not shown).

Several lines of evidence suggest that one role for the phosphorylation of Ser422 is to accelerate phosphorylation at Thr256 by PDK1 and hence the activation of SGK. Thus, GST-SGK is phosphorylated by PDK1 *in vitro* much more slowly than PKB α , but phosphorylation and activation is greatly potentiated by the mutation of Ser422 to Asp (Fig 5). The Ser422 to Asp mutation also greatly increases the activity of SGK expressed in 293 cells (Figs 3 and 9), and this results from increased phosphorylation (presumably at Thr256) because it is abolished by treatment with PP2A (Fig 3) and because the Thr256Ala/Ser422Asp and Thr256Asp/Ser421-Asp double mutants are inactive.

If it is assumed that the Ser422Asp mutation mimics the effect of phosphorylation at this residue, and that the GST-fusion protein behaves similarly to wild-type SGK, then the following model for the activation of SGK would be consistent with the results obtained in this paper. (1) The PtdIns(3,4,5)P₃ generated in response to IGF-1 or hydrogen peroxide

activates PDK2 (or a closely related enzyme), which then phosphorylates SGK at Ser422. (2) The phosphorylation of Ser422 greatly potentiates the rate at which SGK is phosphorylated and activated by PDK1 (or a closely related enzyme). This model explains why the IGF-1 induced or hydrogen-peroxide induced activation of SGK in 293 cells is suppressed by wortmannin (Fig 8B), why the activation of SGK by PDK1 *in vitro* is independent of PtdIns(3,4,5)P₃ (Fig 4) and why the activity of GST-SGK[S422D] is not suppressed by wortmannin. This model is similar to the mechanism proposed for the activation of p70 S6 kinase [15, 16] but, in order to validate it, it will be necessary to find out whether PDK2 is indeed PtdIns(3,4,5)P₃-dependent, and to study the effect of PDK2 on the activation of SGK in the presence and absence of PDK1.

The mechanism of activation of SGK differs from that of PKB in several respects. Firstly, the binding of PtdIns(3,4,5)P₃ to the PH domain of PKB is essential before any activation can take place [7]. Secondly, the interaction of PtdIns(3,4,5)P₃ with the PH domain of PKB causes its recruitment to the plasma membrane, which may facilitate its activation by membrane associated PDK1 and PDK2. Thirdly, PDK1 greatly facilitates the PtdIns(3,4,5)P₃-dependent activation of PKB in lipid vesicles *in vitro*, and may therefore also be critical for the activation of PKB at the plasma membrane *in vivo*. These differences may explain why essentially no activation of PKB occurs *in vivo* until PtdIns(3,4,5)P₃ is elevated and the larger and more rapid activation of PKB by IGF-1 or hydrogen peroxide in 293 cells (Fig 9). However, like the activation of SGK, the activation of PKB may also be dependent on the interaction of PtdIns(3,4,5)P₃ with PDK2.

Like PKB and p70 S6 kinase, SGK phosphorylates peptides at serine or threonine residues that lie in sequences with arginine residues at positions n-3 and n-5 and a large hydrophobic residue at position n+1, where n is the site of phosphorylation. The physiological substrates of SGK are unknown. However, like PKB, SGK is activated by a PtdIns 3-kinase dependent pathway and (unlike p70 S6 kinase) activation is not prevented by the immunosuppressant drug rapamycin. Moreover, when matched for activity towards the standard peptide substrate Crosstide, SGK and PKB α catalysed the inactivation of GSK3 at similar rates (Fig 7). Since GSK3 is thought to be a physiological substrate of PKB [30], it is therefore possible that some of the physiological roles ascribed to PKB based on the overexpression of constitutively active mutants (reviewed in [2]), may actually be mediated by SGK. Since PKB and SGK may well be activated by the same protein kinases in vivo (PDK1 and PDK2), it may not be possible to distinguish their physiological roles by the use of dominant negative mutants. The developments of drugs that inhibit PKB but not SGK, and *vice versa*, or the generation of mouse "knockouts" may be necessary to answer these questions.

Table 1: Comparison of the activity of SGK and PKB α towards synthetic peptides related to Crosstide.

The experiments were carried out with GST- Δ N-SGK and GST-PKB α purified from 293 cells and activated by PDK1. The activities are presented relative to peptide 1 (Crosstide). The concentration of each peptide was 30 μ M. Amino acid substitutions are underlined. The serine residue in Crosstide that is phosphorylated by PKB is marked with an asterisk.

	Peptide	SGK	PKB α
	*		
1	GRPRTSSFAEG	100 %	100 %
2	RPRTSSF	154	160
3	RPRTS <u>A</u> F	<1	<1
4	PRTSSF	<1	<1
5	RPRTSS	10	<1
6	RPRTSTF	156	208
7	RPRAATF	73	55
8	K <u>P</u> RTSSF	2	6
9	RP <u>K</u> TSSF	49	26
10	RPRTSSF	154	160
11	RPRTSS <u>L</u>	135	69
12	RPRTSS <u>V</u>	131	67
13	RPRTSS <u>A</u>	107	26
14	RPRTSS <u>K</u>	146	48
15	RPRTS <u>E</u>	84	21

10 Example 2: Alternative assays

A Scintillation Proximity Assay (SPA) system (Amersham International) is used to assess the incorporation of ^{32}P radioactivity into Crosstide. In this system, the sample (containing GST- ΔN -SGK activated by PDK1 or GST- ΔN -SGK[Ser422Asp] activated by PDK1, the compound to be tested and
5 $[\gamma\text{-}^{32}\text{P}]\text{ATP}$ or $[\gamma\text{-}^{33}\text{P}]\text{ATP}$ is mixed with beads comprising scintillant and antibodies that bind Crosstide. Conveniently this is done in a 96-well format. The plate is then counted using a suitable scintillation counter, using known parameters for ^{32}P or ^{33}P SPA assays. Only ^{32}P or ^{33}P that is in proximity to the scintillant, i.e. only that bound to Crosstide that is then
10 bound by the antibody, is detected.

Example 3: Assay for compounds which modulate SGK activity

An assay is set up with Crosstide, as described in Example 1 or Example 2. Compounds are tested in the assay and those that give rise to inhibition
15 or activation of SGK are selected for further study. Compounds are further tested for effects on PKB α and those that do not affect the phosphorylation of Crosstide by PKB α are selected.

The compounds tested may be compounds selected on the basis of known
20 properties, for example ability to inhibit other protein kinases, such as PKB α , or may be part of a library of compounds assembled for testing in a variety of screens, for example in a "lead generation" screening programme. The compounds may be natural or synthetic, and may be generated by combinatorial chemistry, as known to those skilled in the art.

25 The selected compounds may be used in the design of further compounds for manufacture and test, in order to develop a structure-activity relationship (SAR).

Example 4: Assay for polypeptides that interact with SGK

- 5 A yeast two hybrid assay system is set up to identify polynucleotides encoding polypeptides that are capable of associating with SGK in a stable enough manner to allow transcriptional activation to occur. The polynucleotides are (in separate experiments) cDNAs copied from mRNA from cells that are capable of expressing SGK, before or after stimulation
- 10 capable of stimulating expression of SGK, before or after further stimulation capable of activating the expressed SGK, and from cells which do not express SGK. Interactions which are found in a subset only of these cell types are of particular interest.
- 15 The polypeptide encoded by the polynucleotide is determined by sequencing the insert by the Sanger method as described in Example 1 and well known to those skilled in the art to obtain a predicted amino acid sequence.
- 20 **References.**
 1. Cohen, P., Alessi, D.R. and Cross, D.A.E. (1997) FEBS Lett **410**, 3-10.
 - 25 2. Alessi, D.R. and Cohen, P. (1998) Curr Opin. Genet. Dev. **8**, 55-62
 3. Franke T.F., Yang S.I., Chan T.O., Datta K., Kazlauskas A., Morrison D.K., Kaplan D.R. and Tsichlis, P.N. (1995) Cell **81**, 727-736.

4. Burgering B.M.T. and Coffey P.J. (1995) *Nature* **376**, 599-602.
5. Kohn A.D., Kovachina K.S. and Roth R.A. (1995) *EMBO J.* **14**, 4288-4295.
6. Alessi D.R., Andjelkovic M., Caudwell F.B., Cron P., Morrice N., Cohen P. and Hemmings B.A. (1996) *EMBO J.* **15**, 6541-6551.
7. Alessi D.R., James S.R., Downes, C.P., Holmes, A.B., Gaffney P.R.J., Reese C.B. and Cohen P. (1997) *Curr. Biol.* **7**, 261-269.
8. Stokoe D., Stephens L.R., Copeland T., Gaffney P.R.J., Reese C.B., Painter G.F. (1997) *Science* **277**: 567-570.
9. Alessi D.R., Deak M., Casamayor A., Caudwell F.B., Morrice N., Norman, D.G., Gaffney P., Reese C.B., MacDougall C.N., Harbison D., Ashworth A. & Bownes M. (1997) *Curr. Biol.* **7**, 776-789.
10. Stephens, L., Anderson, K., Stokoe, D., Erdument, H., Painetr, G., Holmes, A.B., Gaffney, P.R.J., Reese, C.B., McCormick, F., Tempst, P., Coadwell, J. and Hawkins, P.T. (1998) *Science* **279**, 710-714.
12. Andjelkovic M., Alessi D.R., Meier R., Fernandez A., Lamb N.J.C., Frech M., Cron P., Cohen P., Lucocq J.M. & Hemming B.A. (1997) *J. Biol. Chem.* **272**, 31515-31524.

13. Goransson, O., Wijkander, J., Mangianello, V. and Degerman, E.
(1998) Blochem. Biophys. Res. Commun. 246, 249-254.
14. Anderson, K.E., Coadwell, J., Stephens, L.R. and Hawkins, P.T.,
5 (1998) Curr. Biol. 8, 684-691
15. Alessi D.R., Kozlowski M.T., Weng Q.P., Morrice N. and Avruch,
J (1998) Curr. Biol. 8, 69-81.
- 10 16. Pullen, N., Dennis. P.B., Andjelkovic, M., Dufner, A., Kozma,
S.C., Hemmings, B.A. and Thomas, G. (1998) Science 279, 707-
710.
17. Le Good, J.A., Ziegler, W.H., Parekh, D.B., Alessi, D.R., Cohen,
15 P. and Parker, P.J. (1998) Science 281(5385):2042-5.
18. Webster, M.K., Goya, Ge, Y., Malyar, A.C. and Firestone, G.L.
(1993) Mol. Cell. Biol. 13, 1031-2040.
- 20 19. Webster, M.K., Goyas, L. and Firestone, G.L. (1993) J.Biol.Chem.
268, 11482-114485
20. Richards, J.S., Fitzpatrick, S.L., Clemens, J.W., Morris, J.K.,
Alliston, T. and Sirois, J. (1995) Hormone Res. 50, 223-255
- 25 21. Waidegger, S, Barth, P., Raber, G. and Lang, F. (1997)
Proc.Natl.Acad.Sci. USA 94, 4440-4445

22. Hollister, R.D., Page, K.J. and Hyman, B.T. (1997) *Neurosci Lett.* **79**, 1111-1119

23. Imaizumi, K., Tsuaa, M., Wanaka, A., Tohyama, M. and Takagi, T. (1994) *Mol. Brain Res.* **26**, 189-196

24. Maiyar, A.C., Hunag, A.J., Phu, P.T., Cha, H.H. and Firestone, G.L. (1996) *J. Biol. Chem.* **271**, 12414-14222

25. Maiyar, A.C., Phu, P.T., Huang, A.J. and Firestone, G.L. (1997) *Mol. Endocrinol.* **11**, 312-329

26. Boyle, W.J., Van der Geer, P. and Hunter T. (1991) *Methods Enzymol.* **201**, 110-149.

27. MacKintosh, C., Beattie, K.A., Klumpp, S., Cohen, P. and Codd, G.A. (1991) *FEBS Lett* **264**, 187-192.

28. Pearson, R.B., Dennis, P.B., Han, J-W., Williamson, N.A., Kozma, S.C., Wettenhall, R.E.H. and Thomas, G. (1995) *EMBO J.* **14**, 5279-5287.

29. Stokoe, D., Campbell, D.G., Nakielny, S., Hidaka, H., Leever, S.J., Marshall, C. and Cohen, P. (1992) *EMBO J.* **11**, 3985-3994.

30. Cross, D.A.E., Alessi, D.R., Cohen, P., Andjelkovic, M. and Hemmings, B.A. (1995) *Nature* **378**, 785-789.

CLAIMS

1. A method of activating serum and glucocorticoid-induced protein
5 kinase (SGK) wherein the SGK is phosphorylated.
2. A method of reducing the activity of phosphorylated SGK wherein the
SGK is dephosphorylated.
- 10 3. The method of claim 1 wherein the SGK is phosphorylated by PDK1
or a variant, fragment, fusion or derivative thereof, or a fusion of a said
variant, fragment or derivative.
- 15 4. The method of claim 2 wherein the SGK is dephosphorylated by PP1
or PP2C or PP2A or a variant, fragment, fusion or derivative thereof, or a
fusion of a said variant, fragment or derivative.
- 20 5. Use of PP1 or PP2C or PP2A or a variant, fragment, fusion or
derivative thereof, or a fusion of a said variant, fragment or derivative in a
method of deactivating and/or dephosphorylating SGK.
- 25 6. Use of PDK1 or a variant, fragment, fusion or derivative thereof, or a
fusion of a said variant, fragment or derivative in a method of activating
and/or phosphorylating SGK.
7. A method of activating SGK wherein SGK is phosphorylated on the
residue equivalent to Thr256 of full-length human SGK.

8. A method of activating SGK wherein SGK is phosphorylated on the residue equivalent to Ser422 of full-length human SGK.
9. A method according to claim 8 wherein SGK is further
5 phosphorylated on the residue equivalent to Thr256.
10. A method according to claim 1 wherein SGK is activated and/or phosphorylated by a preparation containing PDK2 activity.
- 10 11. A fusion polypeptide that comprises human SGK or a variant, fragment or derivative thereof.
12. A fusion polypeptide according to claim 11 wherein the fusion polypeptide comprises glutathione-S-transferase.
15
13. A fusion polypeptide according to claim 11 or 12 or wherein the fusion polypeptide comprises a fragment of human SGK or variant or derivative thereof wherein the N-terminal about 20, 30, 40, 50 or 60 amino acids of human full-length SGK are deleted.
20
14. A polypeptide comprising the amino acid sequence of human SGK or a fragment, variant, derivative or fusion thereof wherein the residue equivalent to serine 422 of full-length human SGK is replaced and/or the residue equivalent to threonine 256 of full-length human SGK is replaced
25 and/or the residue equivalent to lysine 127 is replaced.
15. A polypeptide according to claim 14 wherein the residue equivalent to serine 422 of full-length human SGK is replaced by an aspartate, glutamate, alanine or other non-phosphorylatable residue and/or the

residue equivalent to threonine 256 of full-length human SGK is replaced by an alanine or other non-phosphorylatable residue and/or the residue equivalent to lysine 127 is replaced by an alanine residue.

- 5 16. A polypeptide according to claim 15 wherein the residue equivalent to serine 422 of full-length human SGK is replaced by an aspartate residue and the residues equivalent to threonine 256 and lysine 127 of the full-length human SGK remain as threonine and lysine respectively.
- 10 17. A polypeptide according to claim 16 wherein the N-terminal 20, 30, 40, 50 or 60 amino acids of full-length human SGK are deleted.
18. A polynucleotide encoding a polypeptide as defined in any one of claims 11 to 17 .
- 15 19. A recombinant polynucleotide suitable for expressing a polypeptide as defined in any one of claims 11 to 17 .
- 20 20. A host cell comprising a polynucleotide or as defined in claim 18 or 19.
- 25 21. A method of making the polypeptide as defined in any one of claims 11 to 17 the method comprising culturing a host cell comprising a recombinant polynucleotide or a replicable vector which encodes said polypeptide, and isolating said polypeptide from said host cell.
22. A method according to claim 21 further comprising treating the host cell such that the polypeptide is activated and/or phosphorylated.

00112217.1241490

23. A method according to claim 22 wherein the host cell is treated by exposing it to IGF-1 and/or hydrogen peroxide.

24. A polypeptide obtainable by the method of any one of claims 21 to 5 23.

25. A method of identifying a compound that modulates the activity of SGK wherein activated SGK is used.

10 26. A method of identifying a compound that modulates the activity of SGK, the method comprising contacting a compound with SGK and determining whether the activity of the said SGK is changed compared to the activity of the said SGK in the absence of said compound wherein the activity of SGK is measured by measuring the phosphorylation by SGK, in 15 the presence of a suitable phosphate donor, of a polypeptide comprising an amino acid sequence corresponding to the consensus sequence (Arg/Lys; preferably Arg)-X-(X/Arg)-X-X-(Ser/Thr)-Z, wherein X indicates any amino acid, X/Arg indicates any amino acid, with a preference for arginine, and Z indicates that the amino acid residue is preferably a 20 hydrophobic residue.

27. The method of claim 25 or claim 26 wherein the said SGK or activated SGK is a SGK wherein the residue equivalent to serine 422 of full-length human SGK is replaced by an aspartate residue and the residues 25 equivalent to threonine 256 and lysine 127 of the full-length human SGK remain as threonine and lysine respectively.

28. The method of any one of claims 25 to 27 wherein the SGK is SGK activated by phosphorylation.

29. The method of any one of claims 24 to 28 wherein the activity of the SGK is decreased in the presence of the compound.

5 30. The method according to claim 25 or 26 wherein the activity of the SGK is increased in the presence of the compound.

31. A method of identifying a compound which binds to a physiological substrate of SGK, such as BAD or GSK3, and either enhances or prevents
10 its activation and/or phosphorylation by SGK, the method comprising determining whether a compound enhances or prevents the interaction of the said substrate with SGK or determining whether the compound substantially blocks phosphorylation and/or activation of said substrate by SGK.

15 32. A method of identifying a compound which modulates the activation of SGK by an interacting polypeptide, such as PDK1 or a polypeptide with PDK2 activity, the method comprising determining whether a compound enhances or disrupts the interaction between (a) SGK and (b) the
20 interacting polypeptide, such as PDK1 or a functional equivalent of PDK1 or a preparation containing PDK2 activity, or determining whether the compound modulates activation of the said SGK by the interacting polypeptide, such as PDK1 or a preparation containing PDK2 activity or a functional equivalent thereof.

25 33. A method of identifying a polypeptide that interacts with activated SGK, the method comprising (1) contacting (a) the said SGK with (b) a composition that may contain a polypeptide that interacts with the said activated SGK, (2) detecting the presence of a complex containing the said

50412217-124498

SGK and a polypeptide, and optionally (3) identifying any polypeptide bound to the said protein kinase.

34. A kit of parts useful in carrying out a method according to any one of
5 claims 25 to 33.

35. A kit of parts according to claim 34 comprising SGK, PDK1 or a
functional equivalent thereof, a preparation containing PDK2 activity or a
functional equivalent thereof and/or a substrate of SGK, for example
10 Crosstide or BAD or GSK3.

36. Use of a compound that inhibits SGK but does not inhibit PKB in a
method of identifying a substrate of SGK.

15 37. A compound identifiable or identified by a method according to any
one of claims 25 to 33.

38. A compound according to claim 37 for use in medicine.

20 39. Use of a compound according to claim 37 in the manufacture of a
medicament for treatment of a patient in need of modulation of the activity
of SGK.

40. Use of activated SGK in a screening assay for a drug-like compound
25 or lead compound for the development of a drug-like compound.

41. Use according to claim 39 wherein the patient has cancer.

42. Use according to claim 39 wherein the patient has diabetes or ischaemic disease.


50112917.124498

ABSTRACT

A method of activating serum and glucocorticoid-induced protein kinase
5 (SGK) is provided wherein the SGK is phosphorylated. The SGK may be
phosphorylated by PDK1 and/or a preparation containing PDK2 activity.

A method of identifying a compound that modulates the activity of SGK is
provided, wherein the activity of SGK is measured by measuring the
10 phosphorylation by SGK of a polypeptide comprising an amino acid
sequence corresponding to the consensus sequence (Arg/Lys; preferably
Arg)-X-(X/Arg)-X-X-(Ser/Thr)-Z wherein X indicates any amino acid,
X/Arg indicates any amino acid, with a preference for arginine, and Z
indicates that the amino acid residue is preferably a hydrophobic residue.
15 The SGK may be activated by phosphorylation.

United States Patent & Trademark Office
Office of Initial Patent Examination – Scanning Division



Application deficiencies were found during scanning:

☐ Page(s) _____ of Dedication were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Scanned copy is best available.

60442217-121498

Fig.1


SGK ²⁵⁶TTSTFCGTPEYLAP⁴²²E.....FLGF^SYAPP

PKB α ³⁰⁸TMKTFCGTPEYLAP⁴⁷³E.....FPQF^SYSAS

D70 S6K ²²⁹VTHTFCGTIEYMAPE³⁸⁹.....FLGF^TYVAP


PKC δ ⁵⁰⁷RASTFCGTPDYIAPE⁶⁶⁴.....FAGF^SFVNP

Fig-2



2/10

Fig.3



3/10

Fig.4





Fig. 2



60142247.123498

Fig. 2
5/10





Fig 6
6/10


60112217.121498

Fig.7



7/10

Fig. 8



8/10





Fig 9
9/10

50112217-121198

THIS PAGE BLANK (USPTO)